name	side_effect
Abametapir	The serum concentration of Bortezomib can be increased when it is combined with Abametapir.
Abatacept	The metabolism of Bortezomib can be increased when combined with Abatacept.
Abciximab	The risk or severity of bleeding can be increased when Abciximab is combined with Bortezomib.
Abemaciclib	The serum concentration of Abemaciclib can be increased when it is combined with Bortezomib.
Abiraterone	The serum concentration of Bortezomib can be increased when it is combined with Abiraterone.
Abrocitinib	The serum concentration of Bortezomib can be increased when it is combined with Abrocitinib.
Acalabrutinib	The metabolism of Bortezomib can be decreased when combined with Acalabrutinib.
Acebutolol	The metabolism of Bortezomib can be decreased when combined with Acebutolol.
Acenocoumarol	The metabolism of Acenocoumarol can be decreased when combined with Bortezomib.
Acetaminophen	The metabolism of Bortezomib can be increased when combined with Acetaminophen.
Acetazolamide	The serum concentration of Bortezomib can be increased when it is combined with Acetazolamide.
Acetohexamide	The metabolism of Acetohexamide can be decreased when combined with Bortezomib.
Acetyl sulfisoxazole	The metabolism of Bortezomib can be decreased when combined with Acetyl sulfisoxazole.
Acetyldigitoxin	Acetyldigitoxin may decrease the cardiotoxic activities of Bortezomib.
Acetylsalicylic acid	The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Bortezomib.
Acrivastine	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Acrivastine.
Acyclovir	The metabolism of Acyclovir can be decreased when combined with Bortezomib.
Adagrasib	The serum concentration of Bortezomib can be increased when it is combined with Adagrasib.
Adalimumab	The metabolism of Bortezomib can be increased when combined with Adalimumab.
Adenosine	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Adenosine.
Adenovirus type 7 vaccine live	The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Bortezomib.
Afatinib	The serum concentration of Bortezomib can be increased when it is combined with Afatinib.
Agomelatine	The metabolism of Agomelatine can be decreased when combined with Bortezomib.
Ajmaline	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Ajmaline.
Albendazole	The metabolism of Bortezomib can be increased when combined with Albendazole.
Aldesleukin	The serum concentration of Bortezomib can be increased when it is combined with Aldesleukin.
Alefacept	The risk or severity of adverse effects can be increased when Alefacept is combined with Bortezomib.
Alemtuzumab	The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bortezomib.
Alfuzosin	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Alfuzosin.
Alimemazine	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Alimemazine.
Allogeneic processed thymus tissue	The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Bortezomib.
Allopurinol	The risk or severity of adverse effects can be increased when Allopurinol is combined with Bortezomib.
Almotriptan	The metabolism of Almotriptan can be decreased when combined with Bortezomib.
Alogliptin	The metabolism of Alogliptin can be decreased when combined with Bortezomib.
Alosetron	The metabolism of Bortezomib can be decreased when combined with Alosetron.
Alpelisib	The serum concentration of Bortezomib can be decreased when it is combined with Alpelisib.
Alteplase	The risk or severity of bleeding can be increased when Alteplase is combined with Bortezomib.
Altretamine	The risk or severity of adverse effects can be increased when Bortezomib is combined with Altretamine.
Amantadine	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Amantadine.
Ambrisentan	The serum concentration of Bortezomib can be increased when it is combined with Ambrisentan.
Ambroxol	The risk or severity of methemoglobinemia can be increased when Bortezomib is combined with Ambroxol.
Amifampridine	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Amifampridine.
Aminoglutethimide	The metabolism of Bortezomib can be increased when combined with Aminoglutethimide.
Aminophenazone	The metabolism of Aminophenazone can be decreased when combined with Bortezomib.
Aminophylline	The metabolism of Aminophylline can be decreased when combined with Bortezomib.
Amiodarone	The metabolism of Bortezomib can be decreased when combined with Amiodarone.
Amisulpride	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Amisulpride.
Amitriptyline	The metabolism of Amitriptyline can be decreased when combined with Bortezomib.
Amlodipine	The metabolism of Bortezomib can be decreased when combined with Amlodipine.
Amobarbital	The metabolism of Bortezomib can be increased when combined with Amobarbital.
Amodiaquine	The metabolism of Bortezomib can be decreased when combined with Amodiaquine.
Amoxapine	The metabolism of Amoxapine can be decreased when combined with Bortezomib.
Amphetamine	The metabolism of Bortezomib can be decreased when combined with Amphetamine.
Amprenavir	The metabolism of Bortezomib can be decreased when combined with Amprenavir.
Amsacrine	The risk or severity of adverse effects can be increased when Bortezomib is combined with Amsacrine.
Anagrelide	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Anagrelide.
Anakinra	The metabolism of Bortezomib can be increased when combined with Anakinra.
Anastrozole	The risk or severity of cardiotoxicity can be increased when Bortezomib is combined with Anastrozole.
Ancrod	The risk or severity of bleeding can be increased when Ancrod is combined with Bortezomib.
Anifrolumab	The risk or severity of adverse effects can be increased when Bortezomib is combined with Anifrolumab.
Anistreplase	The risk or severity of bleeding can be increased when Anistreplase is combined with Bortezomib.
Antazoline	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Antazoline.
Anthrax immune globulin human	The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Bortezomib.
Anthrax vaccine	The risk or severity of infection can be increased when Anthrax vaccine is combined with Bortezomib.
Antilymphocyte immunoglobulin (horse)	The risk or severity of adverse effects can be increased when Bortezomib is combined with Antilymphocyte immunoglobulin (horse).
Antipyrine	The metabolism of Antipyrine can be decreased when combined with Bortezomib.
Antithrombin Alfa	The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Bortezomib.
Antithrombin III human	The risk or severity of bleeding can be increased when Antithrombin III human is combined with Bortezomib.
Antithymocyte immunoglobulin (rabbit)	The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bortezomib.
Apalutamide	The metabolism of Bortezomib can be increased when combined with Apalutamide.
Apixaban	The metabolism of Apixaban can be decreased when combined with Bortezomib.
Apomorphine	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Apomorphine.
Apremilast	The metabolism of Bortezomib can be increased when combined with Apremilast.
Aprepitant	The metabolism of Bortezomib can be decreased when combined with Aprepitant.
Ardeparin	The risk or severity of bleeding can be increased when Ardeparin is combined with Bortezomib.
Arformoterol	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Arformoterol.
Argatroban	The risk or severity of bleeding can be increased when Argatroban is combined with Bortezomib.
Aripiprazole	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Aripiprazole.
Aripiprazole lauroxil	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Aripiprazole lauroxil.
Armodafinil	The metabolism of Bortezomib can be increased when combined with Armodafinil.
Arsenic trioxide	The serum concentration of Bortezomib can be increased when it is combined with Arsenic trioxide.
Artemether	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Artemether.
Artenimol	The metabolism of Bortezomib can be decreased when combined with Artenimol.
Articaine	The risk or severity of methemoglobinemia can be increased when Bortezomib is combined with Articaine.
Asciminib	The serum concentration of Bortezomib can be increased when it is combined with Asciminib.
Ascorbic acid	The therapeutic efficacy of Bortezomib can be decreased when used in combination with Ascorbic acid.
Asenapine	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Asenapine.
Astemizole	The serum concentration of Bortezomib can be increased when it is combined with Astemizole.
AstraZeneca COVID-19 Vaccine	The therapeutic efficacy of AstraZeneca COVID-19 Vaccine can be decreased when used in combination with Bortezomib.
Asunaprevir	The metabolism of Bortezomib can be decreased when combined with Asunaprevir.
Atazanavir	The metabolism of Bortezomib can be decreased when combined with Atazanavir.
Atenolol	The metabolism of Atenolol can be decreased when combined with Bortezomib.
Atomoxetine	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Atomoxetine.
Atovaquone	The metabolism of Bortezomib can be decreased when combined with Atovaquone.
Atropine	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Atropine.
Avacopan	The serum concentration of Bortezomib can be increased when it is combined with Avacopan.
Avanafil	The serum concentration of Avanafil can be increased when it is combined with Bortezomib.
Avapritinib	The metabolism of Bortezomib can be decreased when combined with Avapritinib.
Avatrombopag	The serum concentration of Bortezomib can be increased when it is combined with Avatrombopag.
Axitinib	The metabolism of Axitinib can be decreased when combined with Bortezomib.
Azacitidine	The risk or severity of adverse effects can be increased when Bortezomib is combined with Azacitidine.
Azatadine	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Azatadine.
Azathioprine	The risk or severity of adverse effects can be increased when Bortezomib is combined with Azathioprine.
Azelastine	The metabolism of Azelastine can be decreased when combined with Bortezomib.
Azithromycin	The metabolism of Bortezomib can be decreased when combined with Azithromycin.
Bacillus calmette-guerin substrain connaught live antigen	The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Bortezomib.
Bacillus calmette-guerin substrain russian BCG-I live antigen	The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Bortezomib.
Bacillus calmette-guerin substrain tice live antigen	The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Bortezomib.
Baricitinib	The risk or severity of adverse effects can be increased when Bortezomib is combined with Baricitinib.
Basiliximab	The risk or severity of adverse effects can be increased when Basiliximab is combined with Bortezomib.
BCG vaccine	The risk or severity of infection can be increased when BCG vaccine is combined with Bortezomib.
Beclomethasone dipropionate	The metabolism of Bortezomib can be increased when combined with Beclomethasone dipropionate.
Bedaquiline	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Bedaquiline.
Belantamab mafodotin	The serum concentration of Bortezomib can be increased when it is combined with Belantamab mafodotin.
Belatacept	The risk or severity of adverse effects can be increased when Bortezomib is combined with Belatacept.
Belimumab	The risk or severity of adverse effects can be increased when Bortezomib is combined with Belimumab.
Belinostat	The risk or severity of adverse effects can be increased when Bortezomib is combined with Belinostat.
Belumosudil	The serum concentration of Bortezomib can be increased when it is combined with Belumosudil.
Belzutifan	The serum concentration of Bortezomib can be decreased when it is combined with Belzutifan.
Bemiparin	The risk or severity of bleeding can be increased when Bemiparin is combined with Bortezomib.
Bendamustine	The risk or severity of adverse effects can be increased when Bortezomib is combined with Bendamustine.
Bendroflumethiazide	The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Bortezomib.
Benzatropine	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Benzatropine.
Benzocaine	The risk or severity of methemoglobinemia can be increased when Bortezomib is combined with Benzocaine.
Benzthiazide	The risk or severity of neutropenia and thrombocytopenia can be increased when Benzthiazide is combined with Bortezomib.
Benzyl alcohol	The risk or severity of methemoglobinemia can be increased when Bortezomib is combined with Benzyl alcohol.
Bepridil	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Bepridil.
Berotralstat	The serum concentration of Bortezomib can be increased when it is combined with Berotralstat.
Betamethasone	The metabolism of Bortezomib can be increased when combined with Betamethasone.
Betamethasone phosphate	The metabolism of Bortezomib can be increased when combined with Betamethasone phosphate.
Betaxolol	The metabolism of Betaxolol can be decreased when combined with Bortezomib.
Betrixaban	The serum concentration of Bortezomib can be increased when it is combined with Betrixaban.
Bevacizumab	The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Bortezomib.
Bexarotene	The metabolism of Bortezomib can be increased when combined with Bexarotene.
Bicalutamide	The metabolism of Bortezomib can be decreased when combined with Bicalutamide.
Bifonazole	The metabolism of Bortezomib can be decreased when combined with Bifonazole.
Bilastine	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Bilastine.
Bimekizumab	The metabolism of Bortezomib can be increased when combined with Bimekizumab.
Binimetinib	The metabolism of Binimetinib can be decreased when combined with Bortezomib.
Biperiden	The metabolism of Bortezomib can be decreased when combined with Biperiden.
Bisoprolol	The serum concentration of Bortezomib can be increased when it is combined with Bisoprolol.
Bivalirudin	The risk or severity of bleeding can be increased when Bivalirudin is combined with Bortezomib.
Bleomycin	The risk or severity of adverse effects can be increased when Bortezomib is combined with Bleomycin.
Blinatumomab	The risk or severity of adverse effects can be increased when Bortezomib is combined with Blinatumomab.
Boceprevir	The metabolism of Bortezomib can be decreased when combined with Boceprevir.
Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated)	The therapeutic efficacy of Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) can be decreased when used in combination with Bortezomib.
Bosentan	The metabolism of Bortezomib can be increased when combined with Bosentan.
Bosutinib	The serum concentration of Bortezomib can be increased when it is combined with Bosutinib.
Brentuximab vedotin	The serum concentration of Bortezomib can be increased when it is combined with Brentuximab vedotin.
Bretylium	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Bretylium.
Brexpiprazole	The metabolism of Brexpiprazole can be decreased when combined with Bortezomib.
Brivaracetam	The metabolism of Brivaracetam can be decreased when combined with Bortezomib.
Brodalumab	The risk or severity of adverse effects can be increased when Bortezomib is combined with Brodalumab.
Bromazepam	The metabolism of Bromazepam can be decreased when combined with Bortezomib.
Bromotheophylline	The metabolism of Bromotheophylline can be decreased when combined with Bortezomib.
Brompheniramine	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Brompheniramine.
Buclizine	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Buclizine.
Budesonide	The metabolism of Bortezomib can be increased when combined with Budesonide.
Bupivacaine	The risk or severity of methemoglobinemia can be increased when Bortezomib is combined with Bupivacaine.
Buprenorphine	The metabolism of Bortezomib can be decreased when combined with Buprenorphine.
Bupropion	The metabolism of Bortezomib can be decreased when combined with Bupropion.
Buserelin	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Buserelin.
Buspirone	The metabolism of Buspirone can be decreased when combined with Bortezomib.
Busulfan	The risk or severity of adverse effects can be increased when Bortezomib is combined with Busulfan.
Butacaine	The risk or severity of methemoglobinemia can be increased when Bortezomib is combined with Butacaine.
Butalbital	The metabolism of Bortezomib can be increased when combined with Butalbital.
Butamben	The risk or severity of methemoglobinemia can be increased when Bortezomib is combined with Butamben.
Butriptyline	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Butriptyline.
Cabazitaxel	The risk or severity of adverse effects can be increased when Bortezomib is combined with Cabazitaxel.
Cabergoline	The serum concentration of Cabergoline can be increased when it is combined with Bortezomib.
Cabozantinib	The metabolism of Cabozantinib can be decreased when combined with Bortezomib.
Caffeine	The metabolism of Bortezomib can be decreased when combined with Caffeine.
Calcitriol	The metabolism of Bortezomib can be increased when combined with Calcitriol.
Calcium ascorbate	The therapeutic efficacy of Bortezomib can be decreased when used in combination with Calcium ascorbate.
Canagliflozin	The serum concentration of Bortezomib can be increased when it is combined with Canagliflozin.
Canakinumab	The metabolism of Bortezomib can be increased when combined with Canakinumab.
Candesartan cilexetil	The metabolism of Candesartan cilexetil can be decreased when combined with Bortezomib.
Candicidin	The serum concentration of Bortezomib can be increased when it is combined with Candicidin.
Cangrelor	The risk or severity of bleeding can be increased when Cangrelor is combined with Bortezomib.
Cannabidiol	The serum concentration of Bortezomib can be increased when it is combined with Cannabidiol.
Capecitabine	The serum concentration of Bortezomib can be increased when it is combined with Capecitabine.
Caplacizumab	The risk or severity of bleeding can be increased when Caplacizumab is combined with Bortezomib.
Capmatinib	The serum concentration of Bortezomib can be increased when it is combined with Capmatinib.
Capsaicin	The risk or severity of methemoglobinemia can be increased when Bortezomib is combined with Capsaicin.
Carbamazepine	The metabolism of Bortezomib can be increased when combined with Carbamazepine.
Carbinoxamine	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Carbinoxamine.
Carboplatin	The risk or severity of adverse effects can be increased when Bortezomib is combined with Carboplatin.
Carfilzomib	The serum concentration of Bortezomib can be increased when it is combined with Carfilzomib.
Carisoprodol	The metabolism of Carisoprodol can be decreased when combined with Bortezomib.
Carmustine	The risk or severity of adverse effects can be increased when Bortezomib is combined with Carmustine.
Carvedilol	The serum concentration of Bortezomib can be increased when it is combined with Carvedilol.
Cefradine	The metabolism of Bortezomib can be increased when combined with Cefradine.
Celecoxib	The metabolism of Bortezomib can be decreased when combined with Celecoxib.
Celiprolol	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Celiprolol.
Cenobamate	The serum concentration of Bortezomib can be decreased when it is combined with Cenobamate.
Cephalexin	The metabolism of Bortezomib can be decreased when combined with Cephalexin.
Ceritinib	The metabolism of Bortezomib can be decreased when combined with Ceritinib.
Cerivastatin	The metabolism of Bortezomib can be increased when combined with Cerivastatin.
Certolizumab pegol	The metabolism of Bortezomib can be increased when combined with Certolizumab pegol.
Cetirizine	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Cetirizine.
Cevimeline	The metabolism of Bortezomib can be decreased when combined with Cevimeline.
Chlorambucil	The risk or severity of adverse effects can be increased when Bortezomib is combined with Chlorambucil.
Chloramphenicol	The serum concentration of Bortezomib can be increased when it is combined with Chloramphenicol.
Chlorcyclizine	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Chlorcyclizine.
Chloroprocaine	The risk or severity of methemoglobinemia can be increased when Bortezomib is combined with Chloroprocaine.
Chloroquine	The metabolism of Bortezomib can be decreased when combined with Chloroquine.
Chlorothiazide	The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Bortezomib.
Chlorpheniramine	The metabolism of Bortezomib can be decreased when combined with Chlorpheniramine.
Chlorpromazine	The metabolism of Bortezomib can be decreased when combined with Chlorpromazine.
Chlorpropamide	The metabolism of Chlorpropamide can be decreased when combined with Bortezomib.
Chlorprothixene	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Chlorprothixene.
Chlorzoxazone	The metabolism of Chlorzoxazone can be decreased when combined with Bortezomib.
Cholecalciferol	The metabolism of Bortezomib can be decreased when combined with Cholecalciferol.
Ciclesonide	The risk or severity of adverse effects can be increased when Bortezomib is combined with Ciclesonide.
Cilostazol	The serum concentration of Cilostazol can be increased when it is combined with Bortezomib.
Cimetidine	The metabolism of Bortezomib can be decreased when combined with Cimetidine.
Cinacalcet	The metabolism of Bortezomib can be decreased when combined with Cinacalcet.
Cinchocaine	The risk or severity of methemoglobinemia can be increased when Bortezomib is combined with Cinchocaine.
Cinnarizine	The metabolism of Cinnarizine can be decreased when combined with Bortezomib.
Cinoxacin	The metabolism of Bortezomib can be decreased when combined with Cinoxacin.
Ciprofloxacin	The metabolism of Bortezomib can be decreased when combined with Ciprofloxacin.
Cisapride	The metabolism of Bortezomib can be decreased when combined with Cisapride.
Cisplatin	The risk or severity of adverse effects can be increased when Bortezomib is combined with Cisplatin.
Citalopram	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Citalopram.
Cladribine	The risk or severity of adverse effects can be increased when Bortezomib is combined with Cladribine.
Clarithromycin	The metabolism of Bortezomib can be decreased when combined with Clarithromycin.
Clemastine	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Clemastine.
Clevidipine	The metabolism of Bortezomib can be increased when combined with Clevidipine.
Clobazam	The serum concentration of Bortezomib can be increased when it is combined with Clobazam.
Clobetasol propionate	The metabolism of Bortezomib can be increased when combined with Clobetasol propionate.
Clofarabine	The risk or severity of adverse effects can be increased when Bortezomib is combined with Clofarabine.
Clofazimine	The serum concentration of Bortezomib can be increased when it is combined with Clofazimine.
Clofibrate	The metabolism of Bortezomib can be increased when combined with Clofibrate.
Clomifene	The serum concentration of Bortezomib can be increased when it is combined with Clomifene.
Clomipramine	The metabolism of Clomipramine can be decreased when combined with Bortezomib.
Clonidine	The metabolism of Clonidine can be decreased when combined with Bortezomib.
Clopidogrel	The metabolism of Clopidogrel can be decreased when combined with Bortezomib.
Clostridium tetani toxoid antigen (formaldehyde inactivated)	The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Bortezomib.
Clozapine	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Clozapine.
Cobicistat	The metabolism of Bortezomib can be decreased when combined with Cobicistat.
Cobimetinib	The metabolism of Bortezomib can be decreased when combined with Cobimetinib.
Cocaine	The risk or severity of methemoglobinemia can be increased when Bortezomib is combined with Cocaine.
Codeine	The metabolism of Codeine can be decreased when combined with Bortezomib.
Colchicine	The serum concentration of Bortezomib can be increased when it is combined with Colchicine.
Conivaptan	The metabolism of Bortezomib can be decreased when combined with Conivaptan.
Conjugated estrogens	The metabolism of Conjugated estrogens can be decreased when combined with Bortezomib.
Copanlisib	The serum concentration of Copanlisib can be increased when it is combined with Bortezomib.
Corticotropin	The metabolism of Bortezomib can be increased when combined with Corticotropin.
Cortisone acetate	The metabolism of Bortezomib can be increased when combined with Cortisone acetate.
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)	The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Bortezomib.
Crizotinib	The metabolism of Bortezomib can be decreased when combined with Crizotinib.
Curcumin	The metabolism of Bortezomib can be decreased when combined with Curcumin.
Cyanocobalamin	The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Bortezomib.
Cyclizine	The metabolism of Bortezomib can be decreased when combined with Cyclizine.
Cyclobenzaprine	The metabolism of Cyclobenzaprine can be decreased when combined with Bortezomib.
Cyclopenthiazide	The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Bortezomib.
Cyclophosphamide	The metabolism of Bortezomib can be increased when combined with Cyclophosphamide.
Cyclosporine	Bortezomib may increase the immunosuppressive activities of Cyclosporine.
Cyclothiazide	The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Bortezomib.
Cyproheptadine	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Cyproheptadine.
Cyproterone acetate	The metabolism of Bortezomib can be increased when combined with Cyproterone acetate.
Cytarabine	The risk or severity of adverse effects can be increased when Bortezomib is combined with Cytarabine.
Dabigatran	The risk or severity of bleeding can be increased when Dabigatran is combined with Bortezomib.
Dabigatran etexilate	The serum concentration of Bortezomib can be increased when it is combined with Dabigatran etexilate.
Dabrafenib	The serum concentration of Bortezomib can be decreased when it is combined with Dabrafenib.
Dacarbazine	The risk or severity of adverse effects can be increased when Bortezomib is combined with Dacarbazine.
Daclatasvir	The serum concentration of Bortezomib can be increased when it is combined with Daclatasvir.
Dacomitinib	The serum concentration of Bortezomib can be increased when it is combined with Dacomitinib.
Dactinomycin	The risk or severity of adverse effects can be increased when Bortezomib is combined with Dactinomycin.
Dalfopristin	The metabolism of Bortezomib can be decreased when combined with Dalfopristin.
Dalteparin	The risk or severity of bleeding can be increased when Dalteparin is combined with Bortezomib.
Danaparoid	The risk or severity of bleeding can be increased when Danaparoid is combined with Bortezomib.
Danazol	The metabolism of Bortezomib can be decreased when combined with Danazol.
Dapagliflozin	The metabolism of Bortezomib can be decreased when combined with Dapagliflozin.
Dapsone	The metabolism of Dapsone can be decreased when combined with Bortezomib.
Daptomycin	The serum concentration of Bortezomib can be increased when it is combined with Daptomycin.
Darbepoetin alfa	The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Bortezomib.
Darifenacin	The metabolism of Bortezomib can be decreased when combined with Darifenacin.
Darolutamide	The serum concentration of Bortezomib can be increased when it is combined with Darolutamide.
Darunavir	The serum concentration of Bortezomib can be increased when it is combined with Darunavir.
Dasabuvir	The serum concentration of Bortezomib can be increased when it is combined with Dasabuvir.
Dasatinib	The metabolism of Bortezomib can be decreased when combined with Dasatinib.
Daunorubicin	The serum concentration of Bortezomib can be increased when it is combined with Daunorubicin.
Debrisoquine	The metabolism of Debrisoquine can be decreased when combined with Bortezomib.
Decitabine	The risk or severity of adverse effects can be increased when Bortezomib is combined with Decitabine.
Deferasirox	The serum concentration of Bortezomib can be increased when it is combined with Deferasirox.
Defibrotide	The risk or severity of bleeding can be increased when Defibrotide is combined with Bortezomib.
Deflazacort	The metabolism of Bortezomib can be increased when combined with Deflazacort.
Degarelix	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Degarelix.
Delafloxacin	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Delafloxacin.
Delamanid	Bortezomib may increase the QTc-prolonging activities of Delamanid.
Delavirdine	The metabolism of Bortezomib can be decreased when combined with Delavirdine.
Denosumab	The risk or severity of adverse effects can be increased when Denosumab is combined with Bortezomib.
Desflurane	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Desflurane.
Desipramine	The metabolism of Bortezomib can be decreased when combined with Desipramine.
Desirudin	The risk or severity of bleeding can be increased when Desirudin is combined with Bortezomib.
Deslanoside	Deslanoside may decrease the cardiotoxic activities of Bortezomib.
Desloratadine	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Desloratadine.
Desogestrel	The metabolism of Desogestrel can be decreased when combined with Bortezomib.
Desoximetasone	The risk or severity of adverse effects can be increased when Bortezomib is combined with Desoximetasone.
Desvenlafaxine	The metabolism of Bortezomib can be decreased when combined with Desvenlafaxine.
Deucravacitinib	The risk or severity of adverse effects can be increased when Bortezomib is combined with Deucravacitinib.
Deutetrabenazine	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Deutetrabenazine.
Dexamethasone	The serum concentration of Bortezomib can be decreased when it is combined with Dexamethasone.
Dexamethasone acetate	The serum concentration of Bortezomib can be decreased when it is combined with Dexamethasone acetate.
Dexbrompheniramine	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Dexbrompheniramine.
Dexchlorpheniramine maleate	The metabolism of Bortezomib can be decreased when combined with Dexchlorpheniramine maleate.
Dexfenfluramine	The metabolism of Dexfenfluramine can be decreased when combined with Bortezomib.
Dexibuprofen	The metabolism of Dexibuprofen can be decreased when combined with Bortezomib.
Dexlansoprazole	The metabolism of Dexlansoprazole can be decreased when combined with Bortezomib.
Dexmedetomidine	The metabolism of Bortezomib can be decreased when combined with Dexmedetomidine.
Dexrazoxane	The risk or severity of adverse effects can be increased when Bortezomib is combined with Dexrazoxane.
Dextran	The risk or severity of bleeding can be increased when Dextran is combined with Bortezomib.
Dextroamphetamine	The metabolism of Dextroamphetamine can be decreased when combined with Bortezomib.
Dextromethorphan	The metabolism of Dextromethorphan can be decreased when combined with Bortezomib.
Dextropropoxyphene	The serum concentration of Bortezomib can be increased when it is combined with Dextropropoxyphene.
Diacerein	The metabolism of Bortezomib can be decreased when combined with Diacerein.
Diazepam	The metabolism of Diazepam can be decreased when combined with Bortezomib.
Diclofenac	The metabolism of Diclofenac can be decreased when combined with Bortezomib.
Dicloxacillin	The metabolism of Bortezomib can be increased when combined with Dicloxacillin.
Dicoumarol	The risk or severity of bleeding can be increased when Dicoumarol is combined with Bortezomib.
Diethylstilbestrol	The serum concentration of Bortezomib can be increased when it is combined with Diethylstilbestrol.
Difluocortolone	The metabolism of Bortezomib can be increased when combined with Difluocortolone.
Digitoxin	The serum concentration of Digitoxin can be increased when it is combined with Bortezomib.
Digoxin	The serum concentration of Digoxin can be increased when it is combined with Bortezomib.
Dihydralazine	The metabolism of Bortezomib can be decreased when combined with Dihydralazine.
Dihydrocodeine	The metabolism of Dihydrocodeine can be decreased when combined with Bortezomib.
Dihydroergocornine	The metabolism of Bortezomib can be decreased when combined with Dihydroergocornine.
Dihydroergocristine	The metabolism of Bortezomib can be decreased when combined with Dihydroergocristine.
Dihydroergotamine	The serum concentration of Bortezomib can be increased when it is combined with Dihydroergotamine.
Diltiazem	The metabolism of Bortezomib can be decreased when combined with Diltiazem.
Dimenhydrinate	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Dimenhydrinate.
Dimethyl fumarate	The risk or severity of adverse effects can be increased when Bortezomib is combined with Dimethyl fumarate.
Dimethyl sulfoxide	The serum concentration of Bortezomib can be increased when it is combined with Dimethyl sulfoxide.
Dinutuximab	The risk or severity of adverse effects can be increased when Bortezomib is combined with Dinutuximab.
Diosmin	The serum concentration of Bortezomib can be increased when it is combined with Diosmin.
Diphenhydramine	The risk or severity of methemoglobinemia can be increased when Bortezomib is combined with Diphenhydramine.
Dipyridamole	The risk or severity of bleeding can be increased when Dipyridamole is combined with Bortezomib.
Diroximel fumarate	The risk or severity of adverse effects can be increased when Bortezomib is combined with Diroximel fumarate.
Disopyramide	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Disopyramide.
Disulfiram	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Disulfiram.
Docetaxel	The serum concentration of Bortezomib can be increased when it is combined with Docetaxel.
Doconexent	The metabolism of Bortezomib can be decreased when combined with Doconexent.
Dofetilide	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Dofetilide.
Dolasetron	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Dolasetron.
Dolutegravir	The serum concentration of Bortezomib can be increased when it is combined with Dolutegravir.
Domperidone	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Domperidone.
Donepezil	The metabolism of Donepezil can be decreased when combined with Bortezomib.
Dosulepin	The metabolism of Bortezomib can be decreased when combined with Dosulepin.
Doxazosin	The metabolism of Bortezomib can be decreased when combined with Doxazosin.
Doxepin	The metabolism of Doxepin can be decreased when combined with Bortezomib.
Doxorubicin	The serum concentration of Bortezomib can be increased when it is combined with Doxorubicin.
Doxylamine	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Doxylamine.
Dronabinol	The metabolism of Bortezomib can be decreased when combined with Dronabinol.
Dronedarone	The metabolism of Bortezomib can be decreased when combined with Dronedarone.
Droperidol	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Droperidol.
Drospirenone	The metabolism of Bortezomib can be decreased when combined with Drospirenone.
Drotrecogin alfa	The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Bortezomib.
Duloxetine	The metabolism of Bortezomib can be decreased when combined with Duloxetine.
Duvelisib	The metabolism of Bortezomib can be decreased when combined with Duvelisib.
Dyclonine	The risk or severity of methemoglobinemia can be increased when Bortezomib is combined with Dyclonine.
Ebastine	The metabolism of Bortezomib can be decreased when combined with Ebastine.
Ebola Zaire vaccine (live, attenuated)	The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Bortezomib.
Echinacea	The metabolism of Bortezomib can be increased when combined with Echinacea.
Econazole	The metabolism of Bortezomib can be decreased when combined with Econazole.
Eculizumab	The risk or severity of adverse effects can be increased when Bortezomib is combined with Eculizumab.
Edetic acid	The risk or severity of bleeding can be increased when Edetic acid is combined with Bortezomib.
Edoxaban	The serum concentration of Bortezomib can be increased when it is combined with Edoxaban.
Efalizumab	The risk or severity of adverse effects can be increased when Efalizumab is combined with Bortezomib.
Efavirenz	The metabolism of Bortezomib can be decreased when combined with Efavirenz.
Efgartigimod alfa	The risk or severity of adverse effects can be increased when Bortezomib is combined with Efgartigimod alfa.
Elacestrant	The serum concentration of Bortezomib can be increased when it is combined with Elacestrant.
Elagolix	The serum concentration of Bortezomib can be increased when it is combined with Elagolix.
Elbasvir	The serum concentration of Bortezomib can be increased when it is combined with Elbasvir.
Eletriptan	The metabolism of Eletriptan can be decreased when combined with Bortezomib.
Elexacaftor	The metabolism of Bortezomib can be decreased when combined with Elexacaftor.
Eliglustat	The metabolism of Bortezomib can be decreased when combined with Eliglustat.
Eltrombopag	The metabolism of Eltrombopag can be decreased when combined with Bortezomib.
Elvitegravir	The metabolism of Bortezomib can be decreased when combined with Elvitegravir.
Emapalumab	The metabolism of Bortezomib can be increased when combined with Emapalumab.
Emedastine	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Emedastine.
Enasidenib	The serum concentration of Bortezomib can be increased when it is combined with Enasidenib.
Encainide	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Encainide.
Encorafenib	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Encorafenib.
Enfortumab vedotin	The serum concentration of Bortezomib can be increased when it is combined with Enfortumab vedotin.
Enoxacin	The metabolism of Bortezomib can be decreased when combined with Enoxacin.
Enoxaparin	The risk or severity of bleeding can be increased when Enoxaparin is combined with Bortezomib.
Entacapone	The metabolism of Bortezomib can be decreased when combined with Entacapone.
Entecavir	The metabolism of Entecavir can be decreased when combined with Bortezomib.
Entrectinib	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Entrectinib.
Enzalutamide	The metabolism of Bortezomib can be increased when combined with Enzalutamide.
Epinastine	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Epinastine.
Epinephrine	The serum concentration of Bortezomib can be increased when it is combined with Epinephrine.
Epirubicin	The risk or severity of adverse effects can be increased when Bortezomib is combined with Epirubicin.
Epoprostenol	The risk or severity of bleeding can be increased when Epoprostenol is combined with Bortezomib.
Eptifibatide	The risk or severity of bleeding can be increased when Eptifibatide is combined with Bortezomib.
Erdafitinib	The serum concentration of Bortezomib can be increased when it is combined with Erdafitinib.
Ergotamine	The metabolism of Bortezomib can be decreased when combined with Ergotamine.
Eribulin	The risk or severity of adverse effects can be increased when Bortezomib is combined with Eribulin.
Erlotinib	The serum concentration of Bortezomib can be increased when it is combined with Erlotinib.
Ertugliflozin	The serum concentration of Bortezomib can be increased when it is combined with Ertugliflozin.
Erythromycin	The serum concentration of Bortezomib can be increased when it is combined with Erythromycin.
Erythropoietin	The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Bortezomib.
Escitalopram	The serum concentration of Bortezomib can be increased when it is combined with Escitalopram.
Esketamine	The metabolism of Bortezomib can be increased when combined with Esketamine.
Eslicarbazepine	The metabolism of Bortezomib can be increased when combined with Eslicarbazepine.
Eslicarbazepine acetate	The metabolism of Bortezomib can be increased when combined with Eslicarbazepine acetate.
Esmolol	The risk or severity of QTc prolongation can be increased when Esmolol is combined with Bortezomib.
Esomeprazole	The metabolism of Esomeprazole can be decreased when combined with Bortezomib.
Estetrol	The metabolism of Bortezomib can be decreased when combined with Estetrol.
Estradiol	The metabolism of Estradiol can be decreased when combined with Bortezomib.
Estradiol acetate	The metabolism of Bortezomib can be increased when combined with Estradiol acetate.
Estradiol benzoate	The metabolism of Bortezomib can be increased when combined with Estradiol benzoate.
Estradiol cypionate	The metabolism of Bortezomib can be increased when combined with Estradiol cypionate.
Estradiol dienanthate	The metabolism of Bortezomib can be increased when combined with Estradiol dienanthate.
Estradiol valerate	The metabolism of Bortezomib can be increased when combined with Estradiol valerate.
Estramustine	The risk or severity of adverse effects can be increased when Bortezomib is combined with Estramustine.
Estrone sulfate	The metabolism of Bortezomib can be decreased when combined with Estrone sulfate.
Etanercept	The metabolism of Bortezomib can be increased when combined with Etanercept.
Ethambutol	The metabolism of Bortezomib can be decreased when combined with Ethambutol.
Ethanol	The metabolism of Bortezomib can be increased when combined with Ethanol.
Ethinylestradiol	The metabolism of Ethinylestradiol can be decreased when combined with Bortezomib.
Ethosuximide	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Ethosuximide.
Ethyl chloride	The risk or severity of methemoglobinemia can be increased when Bortezomib is combined with Ethyl chloride.
Etidocaine	The risk or severity of methemoglobinemia can be increased when Bortezomib is combined with Etidocaine.
Etodolac	The metabolism of Etodolac can be decreased when combined with Bortezomib.
Etoposide	The risk or severity of adverse effects can be increased when Bortezomib is combined with Etoposide.
Etoricoxib	The serum concentration of Bortezomib can be increased when it is combined with Etoricoxib.
Etravirine	The metabolism of Bortezomib can be increased when combined with Etravirine.
Everolimus	The serum concentration of Bortezomib can be increased when it is combined with Everolimus.
Ezogabine	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Ezogabine.
Famotidine	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Famotidine.
Famtozinameran	The therapeutic efficacy of Famtozinameran can be decreased when used in combination with Bortezomib.
Favipiravir	The serum concentration of Bortezomib can be increased when it is combined with Favipiravir.
Fedratinib	The serum concentration of Bortezomib can be increased when it is combined with Fedratinib.
Felbamate	The metabolism of Bortezomib can be increased when combined with Felbamate.
Felodipine	The metabolism of Bortezomib can be decreased when combined with Felodipine.
Fenfluramine	The metabolism of Bortezomib can be decreased when combined with Fenfluramine.
Fenofibrate	The metabolism of Bortezomib can be decreased when combined with Fenofibrate.
Fesoterodine	The metabolism of Fesoterodine can be decreased when combined with Bortezomib.
Fexinidazole	The risk or severity of adverse effects can be increased when Bortezomib is combined with Fexinidazole.
Fexofenadine	The serum concentration of Bortezomib can be increased when it is combined with Fexofenadine.
Filgotinib	The serum concentration of Bortezomib can be increased when it is combined with Filgotinib.
Fingolimod	Bortezomib may increase the immunosuppressive activities of Fingolimod.
Flecainide	The metabolism of Flecainide can be decreased when combined with Bortezomib.
Flibanserin	The serum concentration of Bortezomib can be increased when it is combined with Flibanserin.
Floxuridine	The risk or severity of adverse effects can be increased when Bortezomib is combined with Floxuridine.
Flucloxacillin	The metabolism of Bortezomib can be increased when combined with Flucloxacillin.
Fluconazole	The serum concentration of Bortezomib can be increased when it is combined with Fluconazole.
Flucytosine	The risk or severity of adverse effects can be increased when Bortezomib is combined with Flucytosine.
Fludarabine	The risk or severity of adverse effects can be increased when Bortezomib is combined with Fludarabine.
Fludrocortisone	The risk or severity of adverse effects can be increased when Bortezomib is combined with Fludrocortisone.
Fluindione	The risk or severity of bleeding can be increased when Fluindione is combined with Bortezomib.
Flunarizine	The metabolism of Flunarizine can be decreased when combined with Bortezomib.
Flunisolide	The metabolism of Bortezomib can be increased when combined with Flunisolide.
Flunitrazepam	The metabolism of Flunitrazepam can be decreased when combined with Bortezomib.
Fluocinolone acetonide	The metabolism of Bortezomib can be increased when combined with Fluocinolone acetonide.
Fluocinonide	The metabolism of Bortezomib can be increased when combined with Fluocinonide.
Fluocortolone	The metabolism of Bortezomib can be increased when combined with Fluocortolone.
Fluorometholone	The risk or severity of adverse effects can be increased when Bortezomib is combined with Fluorometholone.
Fluorouracil	The risk or severity of adverse effects can be increased when Bortezomib is combined with Fluorouracil.
Fluoxetine	The serum concentration of Bortezomib can be increased when it is combined with Fluoxetine.
Flupentixol	The risk or severity of myelosuppression can be increased when Flupentixol is combined with Bortezomib.
Fluphenazine	The metabolism of Bortezomib can be decreased when combined with Fluphenazine.
Fluprednisolone	The risk or severity of adverse effects can be increased when Bortezomib is combined with Fluprednisolone.
Flurbiprofen	The metabolism of Flurbiprofen can be decreased when combined with Bortezomib.
Fluspirilene	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Fluspirilene.
Flutamide	The metabolism of Flutamide can be decreased when combined with Bortezomib.
Fluticasone	The metabolism of Bortezomib can be increased when combined with Fluticasone.
Fluticasone furoate	The risk or severity of adverse effects can be increased when Bortezomib is combined with Fluticasone furoate.
Fluticasone propionate	The serum concentration of Bortezomib can be increased when it is combined with Fluticasone propionate.
Fluvastatin	The metabolism of Bortezomib can be decreased when combined with Fluvastatin.
Fluvoxamine	The metabolism of Bortezomib can be decreased when combined with Fluvoxamine.
Fondaparinux	The risk or severity of bleeding can be increased when Fondaparinux is combined with Bortezomib.
Formestane	The metabolism of Bortezomib can be increased when combined with Formestane.
Formoterol	The metabolism of Formoterol can be decreased when combined with Bortezomib.
Fosamprenavir	The serum concentration of Bortezomib can be increased when it is combined with Fosamprenavir.
Fosaprepitant	The metabolism of Bortezomib can be increased when combined with Fosaprepitant.
Foscarnet	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Foscarnet.
Fosnetupitant	The metabolism of Bortezomib can be decreased when combined with Fosnetupitant.
Fosphenytoin	The metabolism of Bortezomib can be increased when combined with Fosphenytoin.
Fostamatinib	The serum concentration of Bortezomib can be increased when it is combined with Fostamatinib.
Fostemsavir	The serum concentration of Bortezomib can be increased when it is combined with Fostemsavir.
Frovatriptan	The metabolism of Frovatriptan can be decreased when combined with Bortezomib.
Fusidic acid	The metabolism of Bortezomib can be decreased when combined with Fusidic acid.
Futibatinib	The serum concentration of Bortezomib can be increased when it is combined with Futibatinib.
Gadobenic acid	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Gadobenic acid.
Galantamine	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Galantamine.
Gallium nitrate	The risk or severity of adverse effects can be increased when Bortezomib is combined with Gallium nitrate.
Gatifloxacin	The metabolism of Bortezomib can be decreased when combined with Gatifloxacin.
Gefitinib	The metabolism of Bortezomib can be decreased when combined with Gefitinib.
Gemcitabine	The risk or severity of adverse effects can be increased when Bortezomib is combined with Gemcitabine.
Gemfibrozil	The metabolism of Bortezomib can be decreased when combined with Gemfibrozil.
Gemifloxacin	The metabolism of Bortezomib can be decreased when combined with Gemifloxacin.
Gemtuzumab ozogamicin	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bortezomib.
Gilteritinib	The metabolism of Bortezomib can be decreased when combined with Gilteritinib.
Ginkgo biloba	The metabolism of Bortezomib can be decreased when combined with Ginkgo biloba.
Givosiran	The serum concentration of Bortezomib can be increased when it is combined with Givosiran.
Glasdegib	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Glasdegib.
Glatiramer	The risk or severity of adverse effects can be increased when Bortezomib is combined with Glatiramer.
Glecaprevir	The serum concentration of Bortezomib can be increased when it is combined with Glecaprevir.
Gliclazide	The metabolism of Gliclazide can be decreased when combined with Bortezomib.
Glimepiride	The metabolism of Glimepiride can be decreased when combined with Bortezomib.
Glipizide	The metabolism of Glipizide can be decreased when combined with Bortezomib.
Gliquidone	The metabolism of Gliquidone can be decreased when combined with Bortezomib.
Glyburide	The metabolism of Bortezomib can be decreased when combined with Glyburide.
Glycerol phenylbutyrate	The metabolism of Bortezomib can be increased when combined with Glycerol phenylbutyrate.
Golimumab	The metabolism of Bortezomib can be increased when combined with Golimumab.
Goserelin	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Goserelin.
Granisetron	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Granisetron.
Grapefruit	The serum concentration of Bortezomib can be increased when it is combined with Grapefruit.
Grazoprevir	The serum concentration of Bortezomib can be increased when it is combined with Grazoprevir.
Grepafloxacin	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Grepafloxacin.
Griseofulvin	The metabolism of Bortezomib can be increased when combined with Griseofulvin.
GSK-3844766A	The therapeutic efficacy of GSK-3844766A can be decreased when used in combination with Bortezomib.
Guanabenz	The metabolism of Guanabenz can be decreased when combined with Bortezomib.
Guselkumab	The risk or severity of adverse effects can be increased when Bortezomib is combined with Guselkumab.
Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen	The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Bortezomib.
Halofantrine	The metabolism of Bortezomib can be decreased when combined with Halofantrine.
Haloperidol	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Haloperidol.
Halothane	The metabolism of Halothane can be decreased when combined with Bortezomib.
Heparin	The risk or severity of bleeding can be increased when Heparin is combined with Bortezomib.
Hepatitis A Vaccine	The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Bortezomib.
Hepatitis B Vaccine (Recombinant)	The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Bortezomib.
Histrelin	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Histrelin.
Human adenovirus e serotype 4 strain cl-68578 antigen	The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Bortezomib.
Hydralazine	The serum concentration of Bortezomib can be increased when it is combined with Hydralazine.
Hydrochlorothiazide	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Hydrochlorothiazide.
Hydrocortamate	The metabolism of Bortezomib can be increased when combined with Hydrocortamate.
Hydrocortisone	The metabolism of Bortezomib can be increased when combined with Hydrocortisone.
Hydrocortisone acetate	The metabolism of Bortezomib can be increased when combined with Hydrocortisone acetate.
Hydrocortisone butyrate	The metabolism of Bortezomib can be increased when combined with Hydrocortisone butyrate.
Hydrocortisone succinate	The metabolism of Bortezomib can be increased when combined with Hydrocortisone succinate.
Hydroflumethiazide	The risk or severity of neutropenia and thrombocytopenia can be increased when Hydroflumethiazide is combined with Bortezomib.
Hydromorphone	The metabolism of Hydromorphone can be decreased when combined with Bortezomib.
Hydroxychloroquine	The risk or severity of adverse effects can be increased when Bortezomib is combined with Hydroxychloroquine.
Hydroxyurea	The risk or severity of adverse effects can be increased when Bortezomib is combined with Hydroxyurea.
Hydroxyzine	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Hydroxyzine.
Hyoscyamine	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Hyoscyamine.
Ibandronate	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Ibandronate.
Ibritumomab tiuxetan	The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bortezomib.
Ibrutinib	The risk or severity of adverse effects can be increased when Bortezomib is combined with Ibrutinib.
Ibuprofen	The metabolism of Ibuprofen can be decreased when combined with Bortezomib.
Ibutilide	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Ibutilide.
Icosapent ethyl	The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Bortezomib.
Idarubicin	The risk or severity of adverse effects can be increased when Bortezomib is combined with Idarubicin.
Idelalisib	The risk or severity of adverse effects can be increased when Bortezomib is combined with Idelalisib.
Ifosfamide	The metabolism of Bortezomib can be increased when combined with Ifosfamide.
Iloperidone	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Iloperidone.
Iloprost	The risk or severity of bleeding can be increased when Iloprost is combined with Bortezomib.
Imatinib	The serum concentration of Bortezomib can be increased when it is combined with Imatinib.
Imipramine	The metabolism of Bortezomib can be decreased when combined with Imipramine.
Indacaterol	The serum concentration of Bortezomib can be increased when it is combined with Indacaterol.
Indapamide	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Indapamide.
Indinavir	The metabolism of Bortezomib can be decreased when combined with Indinavir.
Indomethacin	The risk or severity of adverse effects can be increased when Bortezomib is combined with Indomethacin.
Inebilizumab	The risk or severity of infection can be increased when Bortezomib is combined with Inebilizumab.
Infigratinib	The metabolism of Bortezomib can be decreased when combined with Infigratinib.
Infliximab	The metabolism of Bortezomib can be increased when combined with Infliximab.
Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated)	The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Bortezomib.
Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated)	The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Bortezomib.
Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen	The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Bortezomib.
Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated)	The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Bortezomib.
Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated)	The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Bortezomib.
Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen	The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Bortezomib.
Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated)	The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Bortezomib.
Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated)	The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Bortezomib.
Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated)	The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Bortezomib.
Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated)	The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Bortezomib.
Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated)	The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Bortezomib.
Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated)	The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Bortezomib.
Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated)	The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Bortezomib.
Inotersen	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Inotersen.
Inotuzumab ozogamicin	The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Bortezomib.
Insulin beef	The metabolism of Bortezomib can be increased when combined with Insulin beef.
Insulin pork	The metabolism of Bortezomib can be increased when combined with Insulin pork.
Interferon alfa-2a	The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Bortezomib.
Interferon alfa-2b	The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Bortezomib.
Interferon alfa-n1	The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Bortezomib.
Interferon alfa-n3	The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Bortezomib.
Interferon alfacon-1	The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Bortezomib.
Interferon beta-1a	The metabolism of Bortezomib can be decreased when combined with Interferon beta-1a.
Interferon beta-1b	The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Bortezomib.
Interferon gamma-1b	The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Bortezomib.
Ipecac	The metabolism of Ipecac can be decreased when combined with Bortezomib.
Irbesartan	The serum concentration of Bortezomib can be increased when it is combined with Irbesartan.
Irinotecan	The risk or severity of adverse effects can be increased when Bortezomib is combined with Irinotecan.
Isavuconazole	The serum concentration of Bortezomib can be increased when it is combined with Isavuconazole.
Isavuconazonium	The serum concentration of Bortezomib can be increased when it is combined with Isavuconazonium.
Isoflurane	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Isoflurane.
Isoniazid	The metabolism of Bortezomib can be decreased when combined with Isoniazid.
Isradipine	The metabolism of Bortezomib can be decreased when combined with Isradipine.
Istradefylline	The serum concentration of Bortezomib can be increased when it is combined with Istradefylline.
Itraconazole	The metabolism of Bortezomib can be decreased when combined with Itraconazole.
Ivabradine	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Ivabradine.
Ivacaftor	The serum concentration of Bortezomib can be increased when it is combined with Ivacaftor.
Ivosidenib	The metabolism of Bortezomib can be increased when combined with Ivosidenib.
Ixabepilone	The serum concentration of Bortezomib can be increased when it is combined with Ixabepilone.
Ixekizumab	The risk or severity of adverse effects can be increased when Bortezomib is combined with Ixekizumab.
Janssen COVID-19 Vaccine	The therapeutic efficacy of Janssen COVID-19 Vaccine can be decreased when used in combination with Bortezomib.
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)	The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Bortezomib.
Ketamine	The metabolism of Ketamine can be decreased when combined with Bortezomib.
Ketazolam	The serum concentration of Bortezomib can be increased when it is combined with Ketazolam.
Ketoconazole	The metabolism of Bortezomib can be decreased when combined with Ketoconazole.
Ketorolac	The metabolism of Ketorolac can be decreased when combined with Bortezomib.
Labetalol	The metabolism of Labetalol can be decreased when combined with Bortezomib.
Lacidipine	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Lacidipine.
Lacosamide	The metabolism of Bortezomib can be decreased when combined with Lacosamide.
Lamotrigine	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Lamotrigine.
Lanreotide	The metabolism of Bortezomib can be decreased when combined with Lanreotide.
Lansoprazole	The metabolism of Lansoprazole can be decreased when combined with Bortezomib.
Lapatinib	The serum concentration of Bortezomib can be increased when it is combined with Lapatinib.
Larotrectinib	The serum concentration of Bortezomib can be increased when it is combined with Larotrectinib.
Lasmiditan	The serum concentration of Bortezomib can be increased when it is combined with Lasmiditan.
Ledipasvir	The serum concentration of Bortezomib can be increased when it is combined with Ledipasvir.
Lefamulin	Lefamulin may increase the QTc-prolonging activities of Bortezomib.
Leflunomide	The risk or severity of adverse effects can be increased when Bortezomib is combined with Leflunomide.
Lemborexant	The serum concentration of Bortezomib can be increased when it is combined with Lemborexant.
Lenalidomide	The risk or severity of adverse effects can be increased when Bortezomib is combined with Lenalidomide.
Leniolisib	The metabolism of Bortezomib can be decreased when combined with Leniolisib.
Lenvatinib	The serum concentration of Bortezomib can be increased when it is combined with Lenvatinib.
Lepirudin	The risk or severity of bleeding can be increased when Lepirudin is combined with Bortezomib.
Lesinurad	The metabolism of Bortezomib can be increased when combined with Lesinurad.
Letermovir	The serum concentration of Bortezomib can be increased when it is combined with Letermovir.
Leuprolide	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Leuprolide.
Levacetylmethadol	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Levacetylmethadol.
Levobetaxolol	The metabolism of Levobetaxolol can be decreased when combined with Bortezomib.
Levobupivacaine	The risk or severity of methemoglobinemia can be increased when Bortezomib is combined with Levobupivacaine.
Levocabastine	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Levocabastine.
Levocetirizine	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Levocetirizine.
Levofloxacin	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Levofloxacin.
Levoketoconazole	The metabolism of Bortezomib can be decreased when combined with Levoketoconazole.
Levomenthol	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Levomenthol.
Levomilnacipran	The metabolism of Levomilnacipran can be decreased when combined with Bortezomib.
Levosimendan	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Levosimendan.
Levothyroxine	The serum concentration of Bortezomib can be decreased when it is combined with Levothyroxine.
Lidocaine	The risk or severity of methemoglobinemia can be increased when Bortezomib is combined with Lidocaine.
Lidoflazine	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Lidoflazine.
Linagliptin	The serum concentration of Bortezomib can be increased when it is combined with Linagliptin.
Linezolid	The risk or severity of adverse effects can be increased when Bortezomib is combined with Linezolid.
Lipegfilgrastim	Bortezomib may increase the myelosuppressive activities of Lipegfilgrastim.
Lisdexamfetamine	The metabolism of Bortezomib can be decreased when combined with Lisdexamfetamine.
Lisuride	The metabolism of Lisuride can be decreased when combined with Bortezomib.
Lofexidine	The metabolism of Lofexidine can be decreased when combined with Bortezomib.
Lomefloxacin	The metabolism of Lomefloxacin can be decreased when combined with Bortezomib.
Lomitapide	The serum concentration of Bortezomib can be increased when it is combined with Lomitapide.
Lomustine	The risk or severity of adverse effects can be increased when Bortezomib is combined with Lomustine.
Lonafarnib	The metabolism of Bortezomib can be decreased when combined with Lonafarnib.
Lonapegsomatropin	The metabolism of Bortezomib can be increased when combined with Lonapegsomatropin.
Loncastuximab tesirine	The serum concentration of Bortezomib can be increased when it is combined with Loncastuximab tesirine.
Loperamide	The serum concentration of Bortezomib can be increased when it is combined with Loperamide.
Lopinavir	The serum concentration of Bortezomib can be increased when it is combined with Lopinavir.
Loratadine	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Loratadine.
Lorcaserin	The metabolism of Bortezomib can be decreased when combined with Lorcaserin.
Lorlatinib	The serum concentration of Bortezomib can be decreased when it is combined with Lorlatinib.
Lornoxicam	The metabolism of Lornoxicam can be decreased when combined with Bortezomib.
Lorpiprazole	The metabolism of Lorpiprazole can be decreased when combined with Bortezomib.
Losartan	The serum concentration of Bortezomib can be increased when it is combined with Losartan.
Lovastatin	The metabolism of Bortezomib can be decreased when combined with Lovastatin.
Loxapine	The serum concentration of Bortezomib can be increased when it is combined with Loxapine.
Lumacaftor	The metabolism of Bortezomib can be increased when combined with Lumacaftor.
Lumefantrine	The metabolism of Bortezomib can be decreased when combined with Lumefantrine.
Lumiracoxib	The metabolism of Lumiracoxib can be decreased when combined with Bortezomib.
Lurasidone	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Lurasidone.
Lusutrombopag	The serum concentration of Bortezomib can be increased when it is combined with Lusutrombopag.
Lynestrenol	The metabolism of Lynestrenol can be decreased when combined with Bortezomib.
Macimorelin	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Macimorelin.
Magnesium	The serum concentration of Magnesium can be decreased when it is combined with Bortezomib.
Manidipine	The metabolism of Bortezomib can be decreased when combined with Manidipine.
Mannitol	The serum concentration of Bortezomib can be increased when it is combined with Mannitol.
Maprotiline	The metabolism of Maprotiline can be decreased when combined with Bortezomib.
Maribavir	The serum concentration of Bortezomib can be increased when it is combined with Maribavir.
Mavacamten	The serum concentration of Mavacamten can be increased when it is combined with Bortezomib.
Measles virus vaccine live attenuated	The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Bortezomib.
Mechlorethamine	The risk or severity of adverse effects can be increased when Bortezomib is combined with Mechlorethamine.
Meclizine	The metabolism of Meclizine can be decreased when combined with Bortezomib.
Medroxyprogesterone acetate	The metabolism of Bortezomib can be increased when combined with Medroxyprogesterone acetate.
Mefenamic acid	The metabolism of Mefenamic acid can be decreased when combined with Bortezomib.
Mefloquine	The serum concentration of Bortezomib can be increased when it is combined with Mefloquine.
Melatonin	The metabolism of Melatonin can be decreased when combined with Bortezomib.
Meloxicam	The risk or severity of methemoglobinemia can be increased when Bortezomib is combined with Meloxicam.
Melphalan	The risk or severity of adverse effects can be increased when Bortezomib is combined with Melphalan.
Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine	The therapeutic efficacy of Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine can be decreased when used in combination with Bortezomib.
Meperidine	The metabolism of Bortezomib can be decreased when combined with Meperidine.
Mephenytoin	The metabolism of Mephenytoin can be decreased when combined with Bortezomib.
Mepivacaine	The risk or severity of methemoglobinemia can be increased when Bortezomib is combined with Mepivacaine.
Mepolizumab	The risk or severity of adverse effects can be increased when Bortezomib is combined with Mepolizumab.
Meprednisone	The metabolism of Bortezomib can be increased when combined with Meprednisone.
Mepyramine	The metabolism of Bortezomib can be decreased when combined with Mepyramine.
Mercaptopurine	The risk or severity of adverse effects can be increased when Bortezomib is combined with Mercaptopurine.
Mesoridazine	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Mesoridazine.
Mestranol	The metabolism of Mestranol can be decreased when combined with Bortezomib.
Metamfetamine	The metabolism of Metamfetamine can be decreased when combined with Bortezomib.
Methadone	The serum concentration of Bortezomib can be increased when it is combined with Methadone.
Methimazole	The metabolism of Bortezomib can be decreased when combined with Methimazole.
Methotrexate	The risk or severity of adverse effects can be increased when Bortezomib is combined with Methotrexate.
Methotrimeprazine	The metabolism of Bortezomib can be decreased when combined with Methotrimeprazine.
Methoxsalen	The metabolism of Bortezomib can be decreased when combined with Methoxsalen.
Methoxy polyethylene glycol-epoetin beta	The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Bortezomib.
Methoxyflurane	The metabolism of Methoxyflurane can be decreased when combined with Bortezomib.
Methsuximide	The metabolism of Methsuximide can be decreased when combined with Bortezomib.
Methylene blue	The serum concentration of Bortezomib can be increased when it is combined with Methylene blue.
Methylergometrine	The serum concentration of Bortezomib can be increased when it is combined with Methylergometrine.
Methylphenobarbital	The metabolism of Bortezomib can be increased when combined with Methylphenobarbital.
Methylprednisolone	The metabolism of Bortezomib can be increased when combined with Methylprednisolone.
Methylprednisone	The metabolism of Bortezomib can be decreased when combined with Methylprednisone.
Methysergide	The metabolism of Bortezomib can be decreased when combined with Methysergide.
Metoclopramide	The metabolism of Bortezomib can be decreased when combined with Metoclopramide.
Metoprolol	The metabolism of Bortezomib can be decreased when combined with Metoprolol.
Metreleptin	The metabolism of Bortezomib can be increased when combined with Metreleptin.
Metronidazole	The serum concentration of Bortezomib can be increased when it is combined with Metronidazole.
Metyrapone	The metabolism of Bortezomib can be increased when combined with Metyrapone.
Mexiletine	The metabolism of Bortezomib can be decreased when combined with Mexiletine.
Mianserin	The metabolism of Mianserin can be decreased when combined with Bortezomib.
Miconazole	The metabolism of Bortezomib can be decreased when combined with Miconazole.
Midazolam	The serum concentration of Bortezomib can be increased when it is combined with Midazolam.
Midostaurin	The metabolism of Bortezomib can be increased when combined with Midostaurin.
Mifepristone	The serum concentration of Bortezomib can be decreased when it is combined with Mifepristone.
Milnacipran	The metabolism of Bortezomib can be decreased when combined with Milnacipran.
Minaprine	The metabolism of Minaprine can be decreased when combined with Bortezomib.
Miocamycin	The serum concentration of Bortezomib can be increased when it is combined with Miocamycin.
Mirabegron	The serum concentration of Bortezomib can be increased when it is combined with Mirabegron.
Mirtazapine	The metabolism of Bortezomib can be decreased when combined with Mirtazapine.
Mitapivat	The metabolism of Bortezomib can be increased when combined with Mitapivat.
Mitomycin	The risk or severity of adverse effects can be increased when Bortezomib is combined with Mitomycin.
Mitotane	The metabolism of Bortezomib can be increased when combined with Mitotane.
Mitoxantrone	The risk or severity of adverse effects can be increased when Bortezomib is combined with Mitoxantrone.
Mizolastine	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Mizolastine.
Mobocertinib	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Mobocertinib.
Moclobemide	The metabolism of Moclobemide can be decreased when combined with Bortezomib.
Modafinil	The metabolism of Bortezomib can be increased when combined with Modafinil.
Moderna COVID-19 Vaccine	The therapeutic efficacy of Moderna COVID-19 Vaccine can be decreased when used in combination with Bortezomib.
Modified vaccinia ankara	The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Bortezomib.
Moexipril	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Moexipril.
Mometasone furoate	The metabolism of Bortezomib can be increased when combined with Mometasone furoate.
Monomethyl fumarate	The risk or severity of adverse effects can be increased when Bortezomib is combined with Monomethyl fumarate.
Montelukast	The metabolism of Montelukast can be decreased when combined with Bortezomib.
Moricizine	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Moricizine.
Morphine	The serum concentration of Bortezomib can be increased when it is combined with Morphine.
Mosunetuzumab	The metabolism of Bortezomib can be decreased when combined with Mosunetuzumab.
Moxifloxacin	The metabolism of Bortezomib can be decreased when combined with Moxifloxacin.
Mumps virus strain B level jeryl lynn live antigen	The therapeutic efficacy of Mumps virus strain B level jeryl lynn live antigen can be decreased when used in combination with Bortezomib.
Muromonab	The risk or severity of adverse effects can be increased when Muromonab is combined with Bortezomib.
Mycophenolate mofetil	The risk or severity of adverse effects can be increased when Bortezomib is combined with Mycophenolate mofetil.
Mycophenolic acid	The risk or severity of adverse effects can be increased when Bortezomib is combined with Mycophenolic acid.
Nabilone	The metabolism of Nabilone can be decreased when combined with Bortezomib.
Nabumetone	The metabolism of Nabumetone can be decreased when combined with Bortezomib.
Nadolol	The metabolism of Nadolol can be decreased when combined with Bortezomib.
Nadroparin	The risk or severity of bleeding can be increased when Nadroparin is combined with Bortezomib.
Nafcillin	The metabolism of Bortezomib can be increased when combined with Nafcillin.
Nalidixic acid	The metabolism of Bortezomib can be decreased when combined with Nalidixic acid.
Naproxen	The metabolism of Naproxen can be decreased when combined with Bortezomib.
Natalizumab	The risk or severity of adverse effects can be increased when Bortezomib is combined with Natalizumab.
Nateglinide	The metabolism of Nateglinide can be decreased when combined with Bortezomib.
Nebivolol	The metabolism of Nebivolol can be decreased when combined with Bortezomib.
Nefazodone	The metabolism of Bortezomib can be decreased when combined with Nefazodone.
Nelarabine	The risk or severity of adverse effects can be increased when Bortezomib is combined with Nelarabine.
Nelfinavir	The metabolism of Bortezomib can be decreased when combined with Nelfinavir.
Neratinib	The serum concentration of Bortezomib can be increased when it is combined with Neratinib.
Netupitant	The serum concentration of Bortezomib can be increased when it is combined with Netupitant.
Nevirapine	The metabolism of Bortezomib can be decreased when combined with Nevirapine.
Niacin	The serum concentration of Bortezomib can be increased when it is combined with Niacin.
Niacinamide ascorbate	The therapeutic efficacy of Bortezomib can be decreased when used in combination with Niacinamide ascorbate.
Nicardipine	The metabolism of Bortezomib can be decreased when combined with Nicardipine.
Nicergoline	The metabolism of Nicergoline can be decreased when combined with Bortezomib.
Niclosamide	The metabolism of Bortezomib can be decreased when combined with Niclosamide.
Nifedipine	The metabolism of Nifedipine can be decreased when combined with Bortezomib.
Nilotinib	The metabolism of Bortezomib can be decreased when combined with Nilotinib.
Nilutamide	The metabolism of Nilutamide can be decreased when combined with Bortezomib.
Nilvadipine	The metabolism of Bortezomib can be decreased when combined with Nilvadipine.
Nimesulide	The risk or severity of bleeding can be increased when Nimesulide is combined with Bortezomib.
Nimodipine	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Nimodipine.
Nintedanib	The metabolism of Bortezomib can be decreased when combined with Nintedanib.
Nitrendipine	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Nitrendipine.
Norethisterone	The metabolism of Bortezomib can be decreased when combined with Norethisterone.
Norfloxacin	The metabolism of Bortezomib can be decreased when combined with Norfloxacin.
Norgestimate	The serum concentration of Bortezomib can be increased when it is combined with Norgestimate.
Nortriptyline	The metabolism of Nortriptyline can be decreased when combined with Bortezomib.
Noscapine	The serum concentration of Bortezomib can be increased when it is combined with Noscapine.
Nuvaxovid	The therapeutic efficacy of Nuvaxovid can be decreased when used in combination with Bortezomib.
Obeticholic acid	The metabolism of Bortezomib can be decreased when combined with Obeticholic acid.
Obinutuzumab	The risk or severity of adverse effects can be increased when Bortezomib is combined with Obinutuzumab.
Ocrelizumab	Ocrelizumab may increase the immunosuppressive activities of Bortezomib.
Octreotide	The serum concentration of Bortezomib can be increased when it is combined with Octreotide.
Ofatumumab	The risk or severity of adverse effects can be increased when Bortezomib is combined with Ofatumumab.
Ofloxacin	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Ofloxacin.
Olanzapine	The metabolism of Olanzapine can be decreased when combined with Bortezomib.
Olaparib	The metabolism of Bortezomib can be decreased when combined with Olaparib.
Oliceridine	The metabolism of Oliceridine can be decreased when combined with Bortezomib.
Olodaterol	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Olodaterol.
Olutasidenib	The metabolism of Bortezomib can be increased when combined with Olutasidenib.
Omadacycline	The serum concentration of Bortezomib can be increased when it is combined with Omadacycline.
Omaveloxolone	The serum concentration of Bortezomib can be decreased when it is combined with Omaveloxolone.
Ombitasvir	The serum concentration of Bortezomib can be increased when it is combined with Ombitasvir.
Omeprazole	The metabolism of Omeprazole can be decreased when combined with Bortezomib.
Ondansetron	The metabolism of Ondansetron can be decreased when combined with Bortezomib.
Opium	The metabolism of Opium can be decreased when combined with Bortezomib.
Oritavancin	The metabolism of Bortezomib can be increased when combined with Oritavancin.
Orphenadrine	The metabolism of Bortezomib can be decreased when combined with Orphenadrine.
Osilodrostat	The metabolism of Bortezomib can be decreased when combined with Osilodrostat.
Osimertinib	The serum concentration of Bortezomib can be decreased when it is combined with Osimertinib.
Ospemifene	The metabolism of Bortezomib can be decreased when combined with Ospemifene.
Ouabain	Ouabain may decrease the cardiotoxic activities of Bortezomib.
Oxaliplatin	The risk or severity of adverse effects can be increased when Bortezomib is combined with Oxaliplatin.
Oxamniquine	The metabolism of Bortezomib can be decreased when combined with Oxamniquine.
Oxandrolone	The metabolism of Bortezomib can be decreased when combined with Oxandrolone.
Oxatomide	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Oxatomide.
Oxcarbazepine	The metabolism of Bortezomib can be increased when combined with Oxcarbazepine.
Oxetacaine	The risk or severity of methemoglobinemia can be increased when Bortezomib is combined with Oxetacaine.
Oxprenolol	The metabolism of Bortezomib can be decreased when combined with Oxprenolol.
Oxtriphylline	The metabolism of Oxtriphylline can be decreased when combined with Bortezomib.
Oxybuprocaine	The risk or severity of methemoglobinemia can be increased when Bortezomib is combined with Oxybuprocaine.
Oxybutynin	The serum concentration of Bortezomib can be increased when it is combined with Oxybutynin.
Oxycodone	The metabolism of Oxycodone can be decreased when combined with Bortezomib.
Oxymorphone	The metabolism of Oxymorphone can be decreased when combined with Bortezomib.
Oxytocin	The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Bortezomib.
Ozanimod	The risk or severity of adverse effects can be increased when Bortezomib is combined with Ozanimod.
Paclitaxel	The metabolism of Bortezomib can be increased when combined with Paclitaxel.
Pacritinib	The serum concentration of Bortezomib can be increased when it is combined with Pacritinib.
Palbociclib	The serum concentration of Bortezomib can be increased when it is combined with Palbociclib.
Palifermin	The therapeutic efficacy of Palifermin can be decreased when used in combination with Bortezomib.
Paliperidone	The serum concentration of Bortezomib can be increased when it is combined with Paliperidone.
Palonosetron	The metabolism of Palonosetron can be decreased when combined with Bortezomib.
Panobinostat	The metabolism of Bortezomib can be decreased when combined with Panobinostat.
Pantoprazole	The metabolism of Pantoprazole can be decreased when combined with Bortezomib.
Papaverine	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Papaverine.
Paramethadione	The metabolism of Paramethadione can be decreased when combined with Bortezomib.
Parecoxib	The metabolism of Parecoxib can be decreased when combined with Bortezomib.
Paritaprevir	The serum concentration of Bortezomib can be increased when it is combined with Paritaprevir.
Parnaparin	The risk or severity of bleeding can be increased when Parnaparin is combined with Bortezomib.
Paroxetine	The metabolism of Bortezomib can be decreased when combined with Paroxetine.
Pasireotide	The metabolism of Bortezomib can be decreased when combined with Pasireotide.
Pazopanib	The metabolism of Bortezomib can be decreased when combined with Pazopanib.
Pefloxacin	The metabolism of Bortezomib can be decreased when combined with Pefloxacin.
Pegaspargase	The risk or severity of adverse effects can be increased when Pegaspargase is combined with Bortezomib.
Pegcetacoplan	The risk or severity of adverse effects can be increased when Bortezomib is combined with Pegcetacoplan.
Peginesatide	The risk or severity of Thrombosis can be increased when Peginesatide is combined with Bortezomib.
Peginterferon alfa-2a	The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Bortezomib.
Peginterferon alfa-2b	The serum concentration of Bortezomib can be increased when it is combined with Peginterferon alfa-2b.
Peginterferon beta-1a	The risk or severity of adverse effects can be increased when Bortezomib is combined with Peginterferon beta-1a.
Pemetrexed	The risk or severity of adverse effects can be increased when Bortezomib is combined with Pemetrexed.
Penbutolol	The metabolism of Penbutolol can be decreased when combined with Bortezomib.
Penciclovir	The metabolism of Penciclovir can be decreased when combined with Bortezomib.
Penicillamine	The risk or severity of adverse effects can be increased when Bortezomib is combined with Penicillamine.
Pentamidine	The metabolism of Pentamidine can be decreased when combined with Bortezomib.
Pentobarbital	The metabolism of Bortezomib can be increased when combined with Pentobarbital.
Pentosan polysulfate	The risk or severity of bleeding can be increased when Pentosan polysulfate is combined with Bortezomib.
Pentostatin	The risk or severity of adverse effects can be increased when Bortezomib is combined with Pentostatin.
Pentoxifylline	The metabolism of Pentoxifylline can be decreased when combined with Bortezomib.
Perampanel	The metabolism of Bortezomib can be increased when combined with Perampanel.
Perflutren	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Perflutren.
Perhexiline	The metabolism of Bortezomib can be decreased when combined with Perhexiline.
Perphenazine	The metabolism of Bortezomib can be decreased when combined with Perphenazine.
Pertussis vaccine	The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Bortezomib.
Pertuzumab	The risk or severity of cardiotoxicity can be increased when Bortezomib is combined with Pertuzumab.
Pexidartinib	Bortezomib may increase the hepatotoxic activities of Pexidartinib.
Phenformin	The metabolism of Phenformin can be decreased when combined with Bortezomib.
Phenindione	The risk or severity of bleeding can be increased when Phenindione is combined with Bortezomib.
Pheniramine	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Pheniramine.
Phenobarbital	The metabolism of Bortezomib can be increased when combined with Phenobarbital.
Phenol	The risk or severity of methemoglobinemia can be increased when Bortezomib is combined with Phenol.
Phenprocoumon	The risk or severity of bleeding can be increased when Phenprocoumon is combined with Bortezomib.
Phenylalanine	The risk or severity of adverse effects can be increased when Phenylalanine is combined with Bortezomib.
Phenylbutazone	The metabolism of Bortezomib can be increased when combined with Phenylbutazone.
Phenylbutyric acid	The metabolism of Bortezomib can be decreased when combined with Phenylbutyric acid.
Phenylephrine	The metabolism of Bortezomib can be increased when combined with Phenylephrine.
Phenytoin	The metabolism of Bortezomib can be increased when combined with Phenytoin.
Pibrentasvir	The serum concentration of Bortezomib can be increased when it is combined with Pibrentasvir.
Pimavanserin	The metabolism of Bortezomib can be decreased when combined with Pimavanserin.
Pimecrolimus	The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Bortezomib.
Pimozide	The metabolism of Pimozide can be decreased when combined with Bortezomib.
Pinaverium	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Pinaverium.
Pindolol	The metabolism of Bortezomib can be decreased when combined with Pindolol.
Piperaquine	The metabolism of Bortezomib can be decreased when combined with Piperaquine.
Piperazine	The metabolism of Piperazine can be decreased when combined with Bortezomib.
Pipotiazine	The metabolism of Bortezomib can be decreased when combined with Pipotiazine.
Pirfenidone	The risk or severity of adverse effects can be increased when Bortezomib is combined with Pirfenidone.
Piroxicam	The metabolism of Piroxicam can be decreased when combined with Bortezomib.
Pirtobrutinib	The serum concentration of Bortezomib can be increased when it is combined with Pirtobrutinib.
Pitavastatin	The metabolism of Pitavastatin can be decreased when combined with Bortezomib.
Pitolisant	The serum concentration of Bortezomib can be decreased when it is combined with Pitolisant.
Polythiazide	The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Bortezomib.
Pomalidomide	The risk or severity of adverse effects can be increased when Bortezomib is combined with Pomalidomide.
Ponatinib	The serum concentration of Bortezomib can be increased when it is combined with Ponatinib.
Ponesimod	The risk or severity of bradycardia can be increased when Ponesimod is combined with Bortezomib.
Posaconazole	The metabolism of Bortezomib can be decreased when combined with Posaconazole.
Practolol	The metabolism of Practolol can be decreased when combined with Bortezomib.
Pralatrexate	The risk or severity of adverse effects can be increased when Bortezomib is combined with Pralatrexate.
Pralsetinib	The serum concentration of Bortezomib can be increased when it is combined with Pralsetinib.
Pramocaine	The risk or severity of methemoglobinemia can be increased when Bortezomib is combined with Pramocaine.
Prasugrel	The risk or severity of bleeding can be increased when Prasugrel is combined with Bortezomib.
Pravastatin	The serum concentration of Bortezomib can be increased when it is combined with Pravastatin.
Praziquantel	The metabolism of Praziquantel can be decreased when combined with Bortezomib.
Prednisolone	The metabolism of Bortezomib can be increased when combined with Prednisolone.
Prednisolone acetate	The metabolism of Bortezomib can be increased when combined with Prednisolone acetate.
Prednisolone phosphate	The serum concentration of Bortezomib can be decreased when it is combined with Prednisolone phosphate.
Prednisone	The risk or severity of adverse effects can be increased when Bortezomib is combined with Prednisone.
Prednisone acetate	The metabolism of Bortezomib can be increased when combined with Prednisone acetate.
Pregabalin	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Pregabalin.
Prenylamine	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Prenylamine.
Pretomanid	The serum concentration of Bortezomib can be increased when it is combined with Pretomanid.
Prilocaine	The risk or severity of methemoglobinemia can be increased when Bortezomib is combined with Prilocaine.
Primaquine	The metabolism of Bortezomib can be decreased when combined with Primaquine.
Primidone	The metabolism of Bortezomib can be increased when combined with Primidone.
Probenecid	The metabolism of Bortezomib can be increased when combined with Probenecid.
Probucol	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Probucol.
Procainamide	The metabolism of Procainamide can be decreased when combined with Bortezomib.
Procaine	The risk or severity of methemoglobinemia can be increased when Bortezomib is combined with Procaine.
Procarbazine	The risk or severity of adverse effects can be increased when Bortezomib is combined with Procarbazine.
Prochlorperazine	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Prochlorperazine.
Progesterone	The metabolism of Progesterone can be decreased when combined with Bortezomib.
Proguanil	The metabolism of Proguanil can be decreased when combined with Bortezomib.
Promazine	The metabolism of Bortezomib can be decreased when combined with Promazine.
Promethazine	The metabolism of Bortezomib can be decreased when combined with Promethazine.
Propafenone	The serum concentration of Bortezomib can be increased when it is combined with Propafenone.
Proparacaine	The risk or severity of methemoglobinemia can be increased when Bortezomib is combined with Proparacaine.
Propofol	The metabolism of Bortezomib can be decreased when combined with Propofol.
Propoxycaine	The risk or severity of methemoglobinemia can be increased when Bortezomib is combined with Propoxycaine.
Propranolol	The serum concentration of Propranolol can be increased when it is combined with Bortezomib.
Propylthiouracil	The risk or severity of adverse effects can be increased when Bortezomib is combined with Propylthiouracil.
Protein C	The risk or severity of bleeding can be increased when Protein C is combined with Bortezomib.
Protein S human	The risk or severity of bleeding can be increased when Protein S human is combined with Bortezomib.
Protriptyline	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Protriptyline.
Quetiapine	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Quetiapine.
Quinidine	The serum concentration of Bortezomib can be increased when it is combined with Quinidine.
Quinine	The metabolism of Bortezomib can be decreased when combined with Quinine.
Quinupristin	The metabolism of Bortezomib can be decreased when combined with Quinupristin.
Rabeprazole	The metabolism of Rabeprazole can be decreased when combined with Bortezomib.
Rabies immune globulin, human	The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Bortezomib.
Rabies virus inactivated antigen, A	The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Bortezomib.
Rabies virus inactivated antigen, B	The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Bortezomib.
Raloxifene	The serum concentration of Bortezomib can be increased when it is combined with Raloxifene.
Raltitrexed	The risk or severity of adverse effects can be increased when Bortezomib is combined with Raltitrexed.
Ramelteon	The metabolism of Ramelteon can be decreased when combined with Bortezomib.
Ranitidine	The metabolism of Bortezomib can be decreased when combined with Ranitidine.
Ranolazine	The serum concentration of Bortezomib can be increased when it is combined with Ranolazine.
Rasagiline	The metabolism of Rasagiline can be decreased when combined with Bortezomib.
Ravulizumab	The risk or severity of adverse effects can be increased when Bortezomib is combined with Ravulizumab.
Reboxetine	The metabolism of Bortezomib can be decreased when combined with Reboxetine.
Regorafenib	The serum concentration of Bortezomib can be increased when it is combined with Regorafenib.
Relugolix	The serum concentration of Bortezomib can be increased when it is combined with Relugolix.
Remdesivir	The metabolism of Bortezomib can be decreased when combined with Remdesivir.
Remoxipride	The metabolism of Remoxipride can be decreased when combined with Bortezomib.
Reserpine	The serum concentration of Bortezomib can be increased when it is combined with Reserpine.
Reteplase	The risk or severity of bleeding can be increased when Reteplase is combined with Bortezomib.
Revefenacin	The serum concentration of Bortezomib can be increased when it is combined with Revefenacin.
Reviparin	The risk or severity of bleeding can be increased when Reviparin is combined with Bortezomib.
Ribociclib	The metabolism of Bortezomib can be decreased when combined with Ribociclib.
Rifabutin	The metabolism of Bortezomib can be increased when combined with Rifabutin.
Rifampicin	The metabolism of Bortezomib can be increased when combined with Rifampicin.
Rifamycin	The metabolism of Bortezomib can be increased when combined with Rifamycin.
Rifapentine	The metabolism of Bortezomib can be increased when combined with Rifapentine.
Rilonacept	The metabolism of Bortezomib can be increased when combined with Rilonacept.
Rilpivirine	The metabolism of Bortezomib can be decreased when combined with Rilpivirine.
Riluzole	The metabolism of Riluzole can be decreased when combined with Bortezomib.
Rimegepant	The serum concentration of Bortezomib can be increased when it is combined with Rimegepant.
Riociguat	The serum concentration of Bortezomib can be increased when it is combined with Riociguat.
Ripretinib	The serum concentration of Bortezomib can be increased when it is combined with Ripretinib.
Risankizumab	The risk or severity of adverse effects can be increased when Bortezomib is combined with Risankizumab.
Risperidone	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Risperidone.
Ritonavir	The serum concentration of Bortezomib can be increased when it is combined with Ritonavir.
Rituximab	The risk or severity of adverse effects can be increased when Rituximab is combined with Bortezomib.
Rivaroxaban	The serum concentration of Bortezomib can be increased when it is combined with Rivaroxaban.
Rofecoxib	The metabolism of Bortezomib can be increased when combined with Rofecoxib.
Roflumilast	Roflumilast may increase the immunosuppressive activities of Bortezomib.
Rolapitant	The metabolism of Bortezomib can be decreased when combined with Rolapitant.
Romidepsin	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Romidepsin.
Ropeginterferon alfa-2b	The risk or severity of adverse effects can be increased when Bortezomib is combined with Ropeginterferon alfa-2b.
Ropivacaine	The risk or severity of methemoglobinemia can be increased when Bortezomib is combined with Ropivacaine.
Rosiglitazone	The metabolism of Rosiglitazone can be decreased when combined with Bortezomib.
Rosoxacin	The metabolism of Bortezomib can be decreased when combined with Rosoxacin.
Rosuvastatin	The metabolism of Bortezomib can be decreased when combined with Rosuvastatin.
Rotavirus vaccine	The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Bortezomib.
Rotigotine	The metabolism of Bortezomib can be decreased when combined with Rotigotine.
Roxithromycin	The metabolism of Bortezomib can be decreased when combined with Roxithromycin.
Rubella virus vaccine	The risk or severity of infection can be increased when Rubella virus vaccine is combined with Bortezomib.
Rucaparib	The metabolism of Bortezomib can be decreased when combined with Rucaparib.
Rufinamide	The metabolism of Bortezomib can be increased when combined with Rufinamide.
Rupatadine	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Rupatadine.
Ruxolitinib	The risk or severity of adverse effects can be increased when Bortezomib is combined with Ruxolitinib.
Salbutamol	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Salbutamol.
Salicylic acid	The metabolism of Salicylic acid can be decreased when combined with Bortezomib.
Salmeterol	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Salmeterol.
Sapropterin	The serum concentration of Bortezomib can be increased when it is combined with Sapropterin.
Saquinavir	The metabolism of Bortezomib can be decreased when combined with Saquinavir.
Sarecycline	The serum concentration of Bortezomib can be increased when it is combined with Sarecycline.
Sarilumab	The metabolism of Bortezomib can be increased when combined with Sarilumab.
Satralizumab	The serum concentration of Bortezomib can be decreased when it is combined with Satralizumab.
Secobarbital	The metabolism of Bortezomib can be increased when combined with Secobarbital.
Secukinumab	The metabolism of Bortezomib can be increased when combined with Secukinumab.
Selegiline	The metabolism of Selegiline can be decreased when combined with Bortezomib.
Selexipag	The serum concentration of Bortezomib can be increased when it is combined with Selexipag.
Selumetinib	The metabolism of Selumetinib can be decreased when combined with Bortezomib.
Sertindole	The metabolism of Sertindole can be decreased when combined with Bortezomib.
Sertraline	The metabolism of Sertraline can be decreased when combined with Bortezomib.
Sevoflurane	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Sevoflurane.
Sildenafil	The serum concentration of Bortezomib can be increased when it is combined with Sildenafil.
Silodosin	The serum concentration of Bortezomib can be increased when it is combined with Silodosin.
Siltuximab	The metabolism of Bortezomib can be increased when combined with Siltuximab.
Simeprevir	The serum concentration of Bortezomib can be increased when it is combined with Simeprevir.
Simvastatin	The serum concentration of Bortezomib can be increased when it is combined with Simvastatin.
Siponimod	The risk or severity of adverse effects can be increased when Bortezomib is combined with Siponimod.
Sipuleucel-T	The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Bortezomib.
Sirolimus	The risk or severity of adverse effects can be increased when Bortezomib is combined with Sirolimus.
Sitagliptin	The serum concentration of Bortezomib can be increased when it is combined with Sitagliptin.
Sitaxentan	The serum concentration of Bortezomib can be increased when it is combined with Sitaxentan.
Smallpox (Vaccinia) Vaccine, Live	The therapeutic efficacy of Smallpox (Vaccinia) Vaccine, Live can be decreased when used in combination with Bortezomib.
Sodium ascorbate	The therapeutic efficacy of Bortezomib can be decreased when used in combination with Sodium ascorbate.
Sodium citrate	The risk or severity of bleeding can be increased when Sodium citrate is combined with Bortezomib.
Sofosbuvir	The serum concentration of Bortezomib can be increased when it is combined with Sofosbuvir.
Solifenacin	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Solifenacin.
Somapacitan	The metabolism of Bortezomib can be increased when combined with Somapacitan.
Somatostatin	The metabolism of Bortezomib can be decreased when combined with Somatostatin.
Somatotropin	The metabolism of Bortezomib can be increased when combined with Somatotropin.
Somatrem	The metabolism of Bortezomib can be increased when combined with Somatrem.
Somatrogon	The metabolism of Bortezomib can be increased when combined with Somatrogon.
Sorafenib	The serum concentration of Bortezomib can be increased when it is combined with Sorafenib.
Sotagliflozin	The serum concentration of Bortezomib can be increased when it is combined with Sotagliflozin.
Sotalol	The metabolism of Sotalol can be decreased when combined with Bortezomib.
Sotorasib	The serum concentration of Bortezomib can be decreased when it is combined with Sotorasib.
Sparfloxacin	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Sparfloxacin.
Sparsentan	The serum concentration of Bortezomib can be decreased when it is combined with Sparsentan.
Spesolimab	The risk or severity of adverse effects can be increased when Bortezomib is combined with Spesolimab.
St. John's Wort	The metabolism of Bortezomib can be increased when combined with St. John's Wort.
Stiripentol	The metabolism of Bortezomib can be decreased when combined with Stiripentol.
Streptokinase	The risk or severity of bleeding can be increased when Streptokinase is combined with Bortezomib.
Streptozocin	The risk or severity of adverse effects can be increased when Bortezomib is combined with Streptozocin.
Sulfadiazine	The metabolism of Bortezomib can be decreased when combined with Sulfadiazine.
Sulfamethizole	The metabolism of Bortezomib can be decreased when combined with Sulfamethizole.
Sulfamethoxazole	The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Bortezomib.
Sulfaphenazole	The metabolism of Bortezomib can be decreased when combined with Sulfaphenazole.
Sulfapyridine	The metabolism of Bortezomib can be decreased when combined with Sulfapyridine.
Sulfasalazine	The risk or severity of adverse effects can be increased when Bortezomib is combined with Sulfasalazine.
Sulfinpyrazone	The metabolism of Bortezomib can be increased when combined with Sulfinpyrazone.
Sulfisoxazole	The metabolism of Bortezomib can be decreased when combined with Sulfisoxazole.
Sulodexide	The risk or severity of bleeding can be increased when Sulodexide is combined with Bortezomib.
Sulpiride	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Sulpiride.
Sultopride	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Sultopride.
Sunitinib	The risk or severity of adverse effects can be increased when Bortezomib is combined with Sunitinib.
Sutimlimab	The risk or severity of adverse effects can be increased when Bortezomib is combined with Sutimlimab.
Suvorexant	The serum concentration of Bortezomib can be increased when it is combined with Suvorexant.
Tacrine	The metabolism of Tacrine can be decreased when combined with Bortezomib.
Tacrolimus	Tacrolimus may increase the immunosuppressive activities of Bortezomib.
Tafenoquine	The metabolism of Tafenoquine can be decreased when combined with Bortezomib.
Talazoparib	The serum concentration of Talazoparib can be increased when it is combined with Bortezomib.
Tamoxifen	The serum concentration of Bortezomib can be increased when it is combined with Tamoxifen.
Tamsulosin	The metabolism of Tamsulosin can be decreased when combined with Bortezomib.
Tasimelteon	The metabolism of Bortezomib can be decreased when combined with Tasimelteon.
Tazemetostat	The metabolism of Bortezomib can be decreased when combined with Tazemetostat.
Technetium Tc-99m sestamibi	The serum concentration of Bortezomib can be increased when it is combined with Technetium Tc-99m sestamibi.
Tecovirimat	The metabolism of Bortezomib can be increased when combined with Tecovirimat.
Tedizolid phosphate	The risk or severity of myelosuppression can be increased when Bortezomib is combined with Tedizolid phosphate.
Tegafur	The metabolism of Tegafur can be decreased when combined with Bortezomib.
Tegaserod	The metabolism of Bortezomib can be decreased when combined with Tegaserod.
Telaprevir	The metabolism of Bortezomib can be decreased when combined with Telaprevir.
Telavancin	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Telavancin.
Telithromycin	The metabolism of Bortezomib can be decreased when combined with Telithromycin.
Telotristat ethyl	The serum concentration of Bortezomib can be decreased when it is combined with Telotristat ethyl.
Temozolomide	The risk or severity of adverse effects can be increased when Bortezomib is combined with Temozolomide.
Temsirolimus	The serum concentration of Bortezomib can be increased when it is combined with Temsirolimus.
Tenecteplase	The risk or severity of bleeding can be increased when Tenecteplase is combined with Bortezomib.
Teniposide	The serum concentration of Bortezomib can be increased when it is combined with Teniposide.
Tenofovir alafenamide	The metabolism of Bortezomib can be decreased when combined with Tenofovir alafenamide.
Tenofovir disoproxil	The serum concentration of Bortezomib can be increased when it is combined with Tenofovir disoproxil.
Tenoxicam	The metabolism of Tenoxicam can be decreased when combined with Bortezomib.
Tepotinib	The serum concentration of Bortezomib can be increased when it is combined with Tepotinib.
Teprotumumab	The risk or severity of adverse effects can be increased when Bortezomib is combined with Teprotumumab.
Terbinafine	The metabolism of Bortezomib can be decreased when combined with Terbinafine.
Terbutaline	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Terbutaline.
Terfenadine	The metabolism of Bortezomib can be decreased when combined with Terfenadine.
Teriflunomide	The serum concentration of Bortezomib can be decreased when it is combined with Teriflunomide.
Terlipressin	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Terlipressin.
Testosterone	The metabolism of Bortezomib can be increased when combined with Testosterone.
Testosterone cypionate	The metabolism of Testosterone cypionate can be decreased when combined with Bortezomib.
Testosterone enanthate	The metabolism of Testosterone enanthate can be decreased when combined with Bortezomib.
Tetrabenazine	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Tetrabenazine.
Tetracaine	The risk or severity of methemoglobinemia can be increased when Bortezomib is combined with Tetracaine.
Tetracycline	The serum concentration of Bortezomib can be increased when it is combined with Tetracycline.
Tezacaftor	The serum concentration of Bortezomib can be increased when it is combined with Tezacaftor.
Thalidomide	The risk or severity of peripheral neuropathy can be increased when Thalidomide is combined with Bortezomib.
Theophylline	The metabolism of Theophylline can be decreased when combined with Bortezomib.
Thiabendazole	The metabolism of Bortezomib can be decreased when combined with Thiabendazole.
Thiamylal	The metabolism of Bortezomib can be increased when combined with Thiamylal.
Thiopental	The metabolism of Thiopental can be decreased when combined with Bortezomib.
Thioridazine	The metabolism of Bortezomib can be decreased when combined with Thioridazine.
Thiotepa	The risk or severity of adverse effects can be increased when Bortezomib is combined with Thiotepa.
Thiothixene	The metabolism of Thiothixene can be decreased when combined with Bortezomib.
Ticagrelor	The serum concentration of Bortezomib can be increased when it is combined with Ticagrelor.
Tick-borne encephalitis vaccine (whole virus, inactivated)	The therapeutic efficacy of Tick-borne encephalitis vaccine (whole virus, inactivated) can be decreased when used in combination with Bortezomib.
Ticlopidine	The metabolism of Ticlopidine can be decreased when combined with Bortezomib.
Timolol	The metabolism of Timolol can be decreased when combined with Bortezomib.
Tinzaparin	The risk or severity of bleeding can be increased when Tinzaparin is combined with Bortezomib.
Tioguanine	The risk or severity of adverse effects can be increased when Bortezomib is combined with Tioguanine.
Tiotropium	The metabolism of Tiotropium can be decreased when combined with Bortezomib.
Tipranavir	The metabolism of Bortezomib can be decreased when combined with Tipranavir.
Tirofiban	The risk or severity of bleeding can be increased when Tirofiban is combined with Bortezomib.
Tivozanib	The serum concentration of Bortezomib can be increased when it is combined with Tivozanib.
Tixocortol	The risk or severity of adverse effects can be increased when Bortezomib is combined with Tixocortol.
Tizanidine	The metabolism of Tizanidine can be decreased when combined with Bortezomib.
Tocainide	The metabolism of Tocainide can be decreased when combined with Bortezomib.
Tocilizumab	The metabolism of Bortezomib can be increased when combined with Tocilizumab.
Tofacitinib	Bortezomib may increase the immunosuppressive activities of Tofacitinib.
Tolazamide	The metabolism of Tolazamide can be decreased when combined with Bortezomib.
Tolbutamide	The metabolism of Tolbutamide can be decreased when combined with Bortezomib.
Tolterodine	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Tolterodine.
Tolvaptan	The serum concentration of Tolvaptan can be increased when it is combined with Bortezomib.
Topiramate	The metabolism of Bortezomib can be increased when combined with Topiramate.
Topotecan	The risk or severity of adverse effects can be increased when Bortezomib is combined with Topotecan.
Torasemide	The metabolism of Bortezomib can be decreased when combined with Torasemide.
Toremifene	The serum concentration of Bortezomib can be increased when it is combined with Toremifene.
Tositumomab	The risk or severity of adverse effects can be increased when Tositumomab is combined with Bortezomib.
Trabectedin	The metabolism of Trabectedin can be decreased when combined with Bortezomib.
Tramadol	The metabolism of Tramadol can be decreased when combined with Bortezomib.
Tranylcypromine	The metabolism of Bortezomib can be decreased when combined with Tranylcypromine.
Trastuzumab	The risk or severity of neutropenia can be increased when Trastuzumab is combined with Bortezomib.
Trastuzumab emtansine	The risk or severity of adverse effects can be increased when Bortezomib is combined with Trastuzumab emtansine.
Trazodone	The risk or severity of QTc prolongation can be increased when Trazodone is combined with Bortezomib.
Treprostinil	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Treprostinil.
Tretinoin	The risk or severity of cardiotoxicity can be increased when Bortezomib is combined with Tretinoin.
Triamcinolone	The metabolism of Bortezomib can be increased when combined with Triamcinolone.
Triamterene	The metabolism of Triamterene can be decreased when combined with Bortezomib.
Trichlormethiazide	The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Bortezomib.
Triclabendazole	The serum concentration of Bortezomib can be increased when it is combined with Triclabendazole.
Trifluoperazine	The metabolism of Trifluoperazine can be decreased when combined with Bortezomib.
Trifluridine	The risk or severity of adverse effects can be increased when Bortezomib is combined with Trifluridine.
Triflusal	The risk or severity of bleeding can be increased when Triflusal is combined with Bortezomib.
Trilaciclib	The metabolism of Bortezomib can be increased when combined with Trilaciclib.
Trilostane	The risk or severity of adverse effects can be increased when Bortezomib is combined with Trilostane.
Trimebutine	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Trimebutine.
Trimethadione	The metabolism of Trimethadione can be decreased when combined with Bortezomib.
Trimethoprim	The metabolism of Trimethoprim can be decreased when combined with Bortezomib.
Trimipramine	The metabolism of Trimipramine can be decreased when combined with Bortezomib.
Tripelennamine	The metabolism of Bortezomib can be decreased when combined with Tripelennamine.
Triprolidine	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Triprolidine.
Triptorelin	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Triptorelin.
Trofinetide	The metabolism of Bortezomib can be decreased when combined with Trofinetide.
Troglitazone	The metabolism of Bortezomib can be increased when combined with Troglitazone.
Troleandomycin	The metabolism of Bortezomib can be decreased when combined with Troleandomycin.
Trospium	The metabolism of Bortezomib can be decreased when combined with Trospium.
Trovafloxacin	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Trovafloxacin.
Tucatinib	Tucatinib may decrease the excretion rate of Bortezomib which could result in a higher serum level.
Typhoid vaccine	The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Bortezomib.
Typhoid Vaccine Live	The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Bortezomib.
Typhoid Vi polysaccharide vaccine	The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Bortezomib.
Ublituximab	The risk or severity of infection can be increased when Ublituximab is combined with Bortezomib.
Ubrogepant	The serum concentration of Bortezomib can be increased when it is combined with Ubrogepant.
Umbralisib	The serum concentration of Bortezomib can be increased when it is combined with Umbralisib.
Umeclidinium	The serum concentration of Bortezomib can be increased when it is combined with Umeclidinium.
Upadacitinib	The risk or severity of adverse effects can be increased when Bortezomib is combined with Upadacitinib.
Urokinase	The risk or severity of bleeding can be increased when Urokinase is combined with Bortezomib.
Valbenazine	The metabolism of Valbenazine can be decreased when combined with Bortezomib.
Valdecoxib	The metabolism of Bortezomib can be decreased when combined with Valdecoxib.
Valoctocogene roxaparvovec	The therapeutic efficacy of Valoctocogene roxaparvovec can be decreased when used in combination with Bortezomib.
Valproic acid	The serum concentration of Bortezomib can be increased when it is combined with Valproic acid.
Valsartan	The metabolism of Bortezomib can be decreased when combined with Valsartan.
Vandetanib	The serum concentration of Bortezomib can be increased when it is combined with Vandetanib.
Vardenafil	The serum concentration of Bortezomib can be increased when it is combined with Vardenafil.
Varicella zoster vaccine (live/attenuated)	The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Bortezomib.
Varicella zoster vaccine (recombinant)	The therapeutic efficacy of Varicella zoster vaccine (recombinant) can be decreased when used in combination with Bortezomib.
Vedolizumab	The risk or severity of adverse effects can be increased when Bortezomib is combined with Vedolizumab.
Velpatasvir	The serum concentration of Bortezomib can be increased when it is combined with Velpatasvir.
Vemurafenib	The serum concentration of Bortezomib can be increased when it is combined with Vemurafenib.
Venetoclax	The serum concentration of Bortezomib can be increased when it is combined with Venetoclax.
Venlafaxine	The metabolism of Bortezomib can be decreased when combined with Venlafaxine.
Verapamil	The serum concentration of Bortezomib can be increased when it is combined with Verapamil.
Vernakalant	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Vernakalant.
Vibrio cholerae CVD 103-HgR strain live antigen	The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Bortezomib.
Vilanterol	The risk or severity of adverse effects can be increased when Bortezomib is combined with Vilanterol.
Vilazodone	The metabolism of Bortezomib can be decreased when combined with Vilazodone.
Viloxazine	The metabolism of Bortezomib can be decreased when combined with Viloxazine.
Vinblastine	The metabolism of Bortezomib can be increased when combined with Vinblastine.
Vincristine	The risk or severity of adverse effects can be increased when Bortezomib is combined with Vincristine.
Vindesine	The risk or severity of adverse effects can be increased when Bortezomib is combined with Vindesine.
Vinflunine	The serum concentration of Vinflunine can be increased when it is combined with Bortezomib.
Vinorelbine	The risk or severity of adverse effects can be increased when Bortezomib is combined with Vinorelbine.
Vitamin E	The metabolism of Bortezomib can be increased when combined with Vitamin E.
Voclosporin	The serum concentration of Bortezomib can be increased when it is combined with Voclosporin.
Vorapaxar	The serum concentration of Bortezomib can be increased when it is combined with Vorapaxar.
Voriconazole	The metabolism of Bortezomib can be decreased when combined with Voriconazole.
Vorinostat	The therapeutic efficacy of Bortezomib can be increased when used in combination with Vorinostat.
Vortioxetine	The metabolism of Vortioxetine can be decreased when combined with Bortezomib.
Voxelotor	The serum concentration of Bortezomib can be increased when it is combined with Voxelotor.
Voxilaprevir	The serum concentration of Bortezomib can be increased when it is combined with Voxilaprevir.
Warfarin	The metabolism of Bortezomib can be increased when combined with Warfarin.
Ximelagatran	The risk or severity of bleeding can be increased when Ximelagatran is combined with Bortezomib.
Yellow fever vaccine	The risk or severity of infection can be increased when Yellow fever vaccine is combined with Bortezomib.
Yohimbine	The metabolism of Yohimbine can be decreased when combined with Bortezomib.
Zafirlukast	The serum concentration of Bortezomib can be increased when it is combined with Zafirlukast.
Zidovudine	The risk or severity of adverse effects can be increased when Bortezomib is combined with Zidovudine.
Zileuton	The metabolism of Bortezomib can be decreased when combined with Zileuton.
Zimelidine	The metabolism of Bortezomib can be decreased when combined with Zimelidine.
Zinc ascorbate	The therapeutic efficacy of Bortezomib can be decreased when used in combination with Zinc ascorbate.
Ziprasidone	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Ziprasidone.
Zolmitriptan	The metabolism of Zolmitriptan can be decreased when combined with Bortezomib.
Zolpidem	The metabolism of Zolpidem can be decreased when combined with Bortezomib.
Zonisamide	The serum concentration of Bortezomib can be increased when it is combined with Zonisamide.
Zopiclone	The metabolism of Zopiclone can be decreased when combined with Bortezomib.
Zotepine	The metabolism of Zotepine can be decreased when combined with Bortezomib.
Zuclopenthixol	The metabolism of Bortezomib can be decreased when combined with Zuclopenthixol.